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1 Zusammenfassung 
Die Interaktion zwischen Tumorzelle und Mikromilieu spielt in der Leukämogenese 
der chronisch lymphatischen Leukämie (CLL) neben den genetischen Schäden eine 
bedeutende Rolle. Eine Stimulation durch extrazelluläre Faktoren ist wichtig für das 
Überleben der CLL-Zelle, denn ohne diese wird die CLL-Zelle außerhalb ihres 
Mikromilieus in den programmierten Zelltod getrieben.  
Vorausgehende Untersuchungen zeigten, dass Macrophage Migration Inhibitory Factor 
(MIF), ein Chemokin mit proinflammatorischer Wirkung, in der CLL überexprimiert ist. 
Da MIF regulatorische Einflüsse auf Zellwachstum, -differenzierung und Apoptose besitzt 
untersucht diese Arbeit die Hypothese, ob MIF eine Rolle bei der Pathogenese der CLL 
zukommt. 
Wir benutzten zu diesem Zweck das Modell der Eµ-T-cell leukemia 1 (TCL1)-transgenen 
Maus (Bichi et al., 2002), bei der eine B-Zell-spezifische Überexpression von TCL1 zu 
einer Akkumulation und Organinfiltration von CD5+IgM+ reifen B-Zellen führt. Die 
transgenen Mäuse entwickeln eine CLL-ähnliche Erkrankung, die sich in einer Leukämie, 
einer Lymphadenopathie, einer Hepatosplenomegalie, Knochenmarksinfiltration sowie 
frühzeitigem Tod nach 8 bis 15 Monaten manifestiert. Der Einfluss von MIF wird durch 
Verpaarung der TCL1+/+ Maus mit der MIF-/- Maus (Fingerle-Rowson et al., 2003) in vivo 
getestet. TCL1+/wt MIF+/+ und TCL1+/wt MIF-/- Mäuse wurden in dieser Arbeit hinsichtlich 
Geschwindigkeit der Leukämieentstehung, Tumorlast, hämatopathologischen 
Veränderungen sowie Proliferations- und Apoptoseverhalten miteinander verglichen. 
Die bekannten MIF-Oberflächenrezeptoren CD74/CD44 und CXCR2 sind auch auf den 
murinen B-Zellen exprimiert. Die TCL1+/wt MIF+/+ Mäuse zeigen schon in der prä-
leukämischen Phase eine erhöhte Anzahl an CD5+IgM+ Zellen und TCL1+/wt MIF+/+ Mäuse 
entwickeln auch ca. 3 Monate vor den TCL1+/wt MIF-/- Mäusen eine periphere Leukämie (p 
= 0.02). Im Alter von 12 Monaten sind Leber und Milz durch Infiltration der Organe durch 
reife, kleinzellige maligne B-Lymphozyten in TCL1+/wt MIF+/+ Mäusen deutlich stärker 
betroffen als die Organe der MIF-defizienten Tiere. Ursächlich hierfür könnte eine 
vermehrte Akkumulation von CD68+ Makrophagen in den leukämisch infiltrierten Milzen 
der TCL1+/wt MIF+/+ Mäuse sein (p < 0.0001), die als sogenannte „nurse-like cells“ (NLCs) 
die Leukämiezellen vor der Apoptose schützen.  
Dazu passt, das die Rate an spontaner Apoptose in MIF-defizienten leukämisch infiltrierten 
Milzen in vivo erhöht ist und ein Trend zu vermehrter Apoptose ex vivo bei den TCL1+/wt 
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MIF-/- Splenozyten zu beobachten ist. Diese MIF-bedingten Unterschiede wirken sich 
sogar auf das Gesamtüberleben aus, denn in den MIF-/- Mäusen beobachten wir eine 
Verlängerung des medianen Überlebens von 80 Tagen (TCL1+/wt MIF+/+ 380 Tage vs. 
TCL1+/wt MIF-/- 460 Tage, p = 0.04). Eine Analyse der erworbenen Genomschäden mittels 
Spektralem Karyotyping (SKY) von Metaphasen leukämischer Splenozyten zeigt 
verschiedene genetische Aberrationen mit Trisomie, Tetraploidie, Translokationen und 
Deletionen in beiden Genotypen. Eine Überexpression des Tumorsuppressors p53 durch 
eine vermutlich inaktivierende Genmutation wurde häufiger in den TCL1+/wt MIF+/+ als in 
den TCL1+/wt MIF-/- Mäusen gefunden. 
 
Unsere Untersuchungen am Eµ-TCL1 Mausmodell zeigen, dass es sich hier um ein 
geeignetes Modell für die Validierung von potentiellen Targetmolekülen bei der 
Pathogenese der CLL handelt. Wie zeigen, dass MIF sowohl in der frühen als auch in der 
späten Phase der CLL-Entstehung als Tumor-Promoter agiert und im Wesentlichen über 
Einflüsse des Mikromilieus auf die Leukämie seine Wirkung ausübt. Weitere 
Untersuchungen schliessen sich noch an, die die Rolle von MIF für die Funktion von 
nurse-like cells bei der CLL und anderen Tumorentitäten sowie den Einfluss von MIF auf 
den Akt-Pathway zum Fokus haben. 
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2 Abstract 
Besides the genetic aberrations the interaction between the tumor cell and its 
microenvironment plays an important role in the leukemogenesis of chronic lymphocytic 
leukemia (CLL). Stimulation via extracellular factors is important for the survival of the 
CLL cell, since without this the CLL cell is driven into apoptosis when taken out of its 
micromilieu.  
Preliminary analyses showed that Macrophage Migration Inhibitory Factor (MIF), a 
chemokine with pro-inflammatory properties, is overexpressed in CLL. As MIF exerts 
regulatory control on cellular growth, -differentiation and apoptosis, this work tests the 
hypothesis whether MIF has a contribution in the pathomechanism of CLL development. 
To this end, we used the Eµ-T-cell leukemia 1 (TCL1) mouse model (Bichi et al., 2002) in 
which B-cell specific overexpression of TCL1 leads to accumulation and organ infiltration 
by CD5+IgM+ mature B cells. The transgenic mice develop a CLL-like disease, which is 
manifested by leukemia, lymphadenopathy, hepatosplenomegaly, bone marrow infiltration 
as well as premature death after 8 to 15 months. The impact of MIF is tested in vivo by 
breeding the TCL1+/+ mouse to the MIF-/- mouse (Fingerle-Rowson et al., 2003). 
In this work, TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice were compared with each other 
regarding the rate of leukemia development, tumor burden, hematopathological alterations, 
overall survival, cytogenetic changes as well as proliferative capacity and apoptosis.  
The known MIF cell surface receptors CD74/CD44 and CXCR2 are also expressed on the 
murine B cells. TCL1+/wt MIF+/+ mice show already in the pre-leukemic phase a higher 
number of CD5+IgM+ cells, and the development of a peripheral leukemia starts about 
three months earlier in TCL1+/wt MIF+/+ mice compared to TCL1+/wt MF-/- animals  
(p = 0.02). At the age of 12 months, organs like liver and spleen are infiltrated to a higher 
degree by small, mature and malignant B lymphocytes in the TCL1+/wt MIF+/+ than in the 
MIF-deficient mice. One reason for this could be the increased accumulation of CD68+ 
macrophages in the leukemia infiltrated spleens and bone marrow of the MIF wildtype 
mice (p < 0.0001). “nurse-like” cells (NLCs) act to protect the leukemic cells from 
apoptosis.  
This fits the observation that the rate of spontaneous apoptosis is elevated in the MIF-
deficient leukemia infiltrated spleens in vivo, and that a trend towards higher rates of 
apoptosis can be seen in splenocytes of the TCL1+/wt MIF-/- mice ex vivo. These MIF-
dependent effects even affect overall survival since in the MIF-/- mice, the overall median 
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survival is prolonged by 80 days (TCL1+/wt MIF+/+ 380 days vs. TCL1+/wt MIF-/- 460 days, 
p = 0.04). An analysis of genomic aberrations by spectral karyotyping (SKY) of 
metaphases from leukemic splenocytes shows distinct genetic damages like trisomy, 
tetraploidy, translocations and deletions in both genotypes. An overexpression of the tumor 
suppressor p53 presumably due to an inactivating gene mutation was found in TCL1+/wt 
MIF+/+ mice at a higher frequency than in TCL1+/wt MIF-/- mice.  
 
Our analysis of the Eµ-TCL1 mouse model shows that this is a valuable model for the 
validation of potential target molecules in the pathogenesis of CLL. We are able to 
demonstrate that MIF acts as a tumor promoter primarily by influencing the micromilieu in 
the early as well as in the late phase of leukemkia development. Further analyses are on the 
way which focus on the role of MIF in the function of the nurse-like cells in CLL and other 
tumor entities and which test the interaction of MIF and Akt.  
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3 Introduction 
3.1 Macrophage Migration Inhibitory Factor (MIF) 
Macrophage migration inhibitory factor (MIF) was first described by the scientists 
Barry Bloom and John David in 1966 when they both independently from each other 
isolated a protein from cultures of antigen-sensitized lymphocytes that could act at a 
distance to inhibit the random movement or migration of phagocytes (Bloom and Bennett 
1966; David 1966). It was one of the first soluble, non-immunoglobulin cytokines which 
could be analysed in vitro. This molecule was named macrophage migration inhibitory 
factor (MIF) and its activity was reported over the next 20 years to alter phagocytosis, 
macrophage adherence, spreading and to increase phagocyte tumoricidal potential (Nathan 
et al., 1971; Nathan et al., 1973; Churchill et al., 1975). 
In 1989, human MIF was cloned and a molecular analysis of the biological, biochemical 
and biophysical properties was approached (Weiser et al., 1989).  
 
3.1.1 Expression pattern of MIF 
MIF protein and MIF mRNA have been detected in a wide variety of tissues and cell 
types. Since there is no cell line or tissue known to be negative for MIF, one can assume 
that MIF is an ubiquitously expressed protein. It seems to be expressed at baseline levels in 
nearly all tissues; however, it can also be induced by a variety of stimuli depending on the 
cellular context.  
Expression of MIF can already be detected at the beginning of life. Kobayashi et al. 
studied the expression of mRNA during embryogenenis of mice and showed co-expression 
of MIF in organogenesis parallel to tissue specification. MIF mRNA was detected in 
somites, precartilage primordia in ribs and vertebrae, branchial arches, limb buds, neural 
tissues, all muscle cell types and during organogenesis of liver, kidney, testis, skin, 
intestine, adrenal gland and pancreas (Suzuki et al., 1996; Kobayashi et al., 1999). This 
broad expression pattern of MIF in embryogenesis continues during adult life. MIF protein 
can be detected constitutively in serum and plasma. This soluble MIF could arise from a 
great variety of tissues in which MIF is synthesised. Historically, MIF was considered to 
be a product of activated T-lymphocytes (David 1966), but immunohistochemical analysis 
of various tissues indicates a broad expression pattern of MIF (Bacher et al., 1997). MIF is 
expressed in cells of the immune system such as monocytes/macrophages (Calandra et al., 
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1994), T- and B-lymphocytes (Bacher et al., 1996; Takahashi et al., 1999), NK-cells (Apte 
et al., 1998), basophiles/mast cells (Chen et al., 1998) and eosinophils (Rossi et al., 1998).  
Endocrine organs such as the anterior pituitary gland (Bernhagen et al., 1993), the adrenal 
cortex, the Leydig-cells of the testis, the epithelial cells of the epididymis and pancreatic β-
cells (Waeber et al., 1997) have been reported to be a source of MIF production (Bacher et 
al., 1997). Other MIF synthesizing cells are smooth and skeletal muscle cells (Benigni et 
al., 2000), gastric parietal cells (Kudo 1998), keratinocytes and fibroblasts (Abe et al., 
2000), hepatocytes and peripheral and central neurons (Bacher et al., 1998). Even 
erythrocytes have been reported to contain MIF (Mizue et al., 2000), although these data 
could be confounded by leukocyte contamination or membrane-bound MIF.  
 
Figure 1: Expression pattern of MIF in humans. MIF is expressed in brain, eye, ear, in the immune 
system (blood, lymphnode, thymus, spleen, bone marrow), in endothelial cells and epithelial cells, 
in the skin and in bone and joints (modified from(Calandra and Roger 2003).  
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3.1.2 Organization of the MIF gene locus 
The gene for murine MIF is located on chromosome 10 (Bozza et al., 1995; Mitchell et 
al., 1995) and the human gene maps to chromosome 22q11.2 (Budarf et al., 1997). Both 
genes are very small (approximately 1.7 kb in size) and show a similar intron-exon 
organization. The gene consists of three exons of 107, 162 and 66 basepairs and two 
introns of 188 and 94 basepairs. The sequence-identity within MIF RNA transcripts 
between mouse and human is very high (70.4%, 86.4% and 67.5% for exons 1, 2, and 3). 
Consensus sequences which indicate the presence of transcription factor binding sites, have 
been found in the murine as well as in the human MIF promoter (Mitchell et al., 1995). 
The promoter region contains enhancer and regulatory binding domains which are 
implicated to respond to the proto-oncogene c-fos (Paralkar and Wistow 1994; Maleszka et 
al., 1998). Other domains are a SP-1 sequence, a cAMP responsive element (CREB) and 
an AP-1 sequence. Further upstream there are a cytokine-1 (CK-1) site and a nuclear 
factor-κB site (NF-κB) (Fig. 2). 
Two polymorphisms of the MIF gene have been found and are associated with 
inflammatory diseases: a G to C transition at position -173 is associated to systemic-onset 
juvenile arthritis (Donn et al., 2004) and a CATT-tetranucleotide repeat of five to eight 
times at position -794 is linked to rheumatoid arthritis (Baugh et al., 2002; Martinez et al., 
2007) (Fig. 2).  
 
Figure 2: Structure of the MIF gene. It is composed of three short exons (green) and two introns 
(pink).  
 
3.1.3 Structure of the MIF protein 
Human and mouse MIF cDNA were cloned from the Jurkat T cell line (Metz and Bucala 
1997), the brain (Paralkar and Wistow 1994), the AtT-20 pituitary cell line (Bernhagen et 
al., 1994) and the recombinant proteins were expressed. In both species the primary protein 
has a length of 115 amino acids and a molecular mass of 12.5 kDa. The initiating 
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methionine is post-translationally removed and the mature protein starts with a proline in 
position 1.  
Determination of the three-dimensional structure of mouse and human MIF was done by 
X-ray crystallography (Kato et al., 1996; Sugimoto et al., 1996; Sun et al., 1996) and by 
NMR (nuclear magnet resonance) -spectroscopy (Muhlhahn et al., 1996) and led to the 
discovery of the protein fold. All X-ray studies showed that MIF is a trimer of identical 
subunits with the overall dimensions of 35 x 50 x 50 Å. The MIF monomer contains two 
antiparallel α-helices and six β-strands, four of which form a mixed β-sheet. Three 
monomers assemble to an α/β structure consisting of six α-helices surrounding three β-
sheets that form a barrel with a solvent accessible channel. This orientation is unusual for 
an eukaryotic protein. Stabilization of the trimer is guaranteed by several hydrogen bonds 
between the β-sheets and between one of the α-helices and the carboxyl-terminus  
(C-terminus). One leucine-rich hydrophobic region is also stabilized by hydrophobic 
bonds.  
 
Figure 3: The active form of MIF as a homotrimer. 
 
Looking at the three-dimensional architecture of MIF and other enzymes, a similarity 
between bacterial tautomerases and human D-dopachrome tautomerase (DDT) can be 
found. In the genome of mice and men, the gene for DDT lies only at 80 kb distance from 
MIF and we know that the MIF/DDT locus had evolved as a duplication event during 
evolution. DDT shares amino acid sequence homology with MIF to about 30%, whereas 
the crystal structure, its overall topology and trimeric formation is almost identical to MIF 
(Sugimoto et al., 1999). The protein GIF (glycosylation inhibition factor) which was 
investigated in the 1990s by Japanese scientists was found to be identical to MIF since its 
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sequence and structure are identical to MIF (Galat et al., 1994; Nishibori et al., 1996; 
Watarai et al., 2000). 
 
3.1.4 Extracellular and intracellular MIF 
Until today two different ways of signaling have been described for MIF; an 
extracellular and an intracellular signaling pathway. 
The first receptor found to bind extracellular MIF was CD74 (Leng et al. 2003). CD74 is a 
nonpolymorphic type II integral membrane protein, which was initially considered to 
function as an MHC class II chaperone only (Stumptner-Cuvelette and Benaroch 2002). 
With the discovery of MIF as a ligand for CD74, its additional role as an accessory 
signaling molecule started to become clearer. In macrophages, MIF binds with a high 
affinity to the extracellular domain of CD74, activating the mitogen activated protein 
kinase (MAPK) pathway and cell proliferation (Leng et al. 2003). CD74 involves other 
receptors for signal transduction and another trans-membrane co-receptor, the adhesion 
molecule CD44, appears to be required for the phosphorylation of the ERK1/2 kinases by 
MIF (Shi et al., 2006). The activation of both receptors is also required for MIF-mediated 
protection of the cell from apoptosis. In B lymphocytes, MIF initiates a signaling cascade 
activating NF-κB via the Src kinase Syk and Akt. This activation is mediated by 
translocation of the CD74-intracellular domain which gets released by intramembrane 
regulated proteolysis (RIP) upon MIF stimulation (Gore et al., 2008) 
MIF was also identified to be a non-cognate ligand for the chemokine receptors CXCR2 
and CXCR4 (Bernhagen et al., 2007). By interaction with those two receptors, MIF is able 
to promote the recruitment of monocytes as well as T cells into inflamed tissue. It is also 
known that CXCR2 co-localizes with CD74 which suggest that MIF may signal via a 
combined CD74/CD44/CXCR2 complex.  
MIF is also abundantly expressed in the cytosol and intracellular MIF involves another 
pathway by direct binding and inhibitory interaction with Jab-1/CSN5 (Jab =  
c-jun activating binding protein). One known function of Jab-1/CSN5 is the coactivation of 
AP-1 transcription (Bernhagen et al., 1993; Rosengren et al., 1996; Bernhagen et al., 1998; 
Kleemann et al., 1998). Jab-1/CSN5 is also the subunit 5 of the COP9 signalosome (CSN) 
which is located in the nucleus and the cytoplasm (Kleemann et al., 2000; Bech-Otschir et 
al., 2001; Chamovitz and Segal 2001). The CSN consists of eight subunits which are 
highly similar to the subunits of the 26S proteasome (Glickman et al., 1998; Henke et al., 
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1999), which is the major proteolytic system of the cell (Hershko and Ciechanover 1998). 
Jab-1 specifically binds to p27Kip1, a cyclin-dependent kinase inhibitor (CDKI), and 
promotes its degradation via the proteasome (Tomoda et al., 1999). Inhibition of Jab-1 by 
MIF antagonizes Jab-1-dependent regulation of p27Kip1 and stabilizes this CDKI 
(Kleemann et al. 2000). Other known targets of Jab-1/CSN5 are the tumor suppressor p53 
or hypoxia-inducing factor-1α (HIF-1α) (Bech-Otschir et al., 2001; Bae et al., 2002).  
 
3.1.5 MIF and tumorigenesis 
In many different tumor entities, MIF is described to be correlated with the cancer 
prognosis. Specifically, this correlation was done for hepatocellular carcinomas, colon 
cancers and prostate cancers (Meyer-Siegler et al., 2002; Legendre et al., 2003; Hira et al., 
2005). Interestingly, MIF seems to affect the two ways of the adaptive immune system, 
namely the Th1 and the Th2 routes. The first route activates macrophages and neutrophils 
by secretion of IL-2, IL-12m IFNγ and TNFα. The Th2 route, which acts as a counterpart 
to Th1 activates cytokines including IL-4, IL-5, IL-13 and IL-10. MIF affects these 
pathways in differently, on the one hand by sustaining the macrophage viability and 
thereby leading to a sustained inflammatory reaction (Mitchell et al., 2002) and on the 
other hand MIF activates the ERK-MAPK pathway and increases thereby cell proliferation 
(Mitchell et al., 2002). MIF is also capable of inducing angiogenesis. In a recent study it 
was shown that MIF enhances the differentiation of endothelial cells to blood vessels 
(Chesney et al., 1999; Amin et al., 2003), and there is evidence that MIF is able to 
modulate VEGF functioning.  
Another mechanism for MIF acting as a tumor promoter could be the inhibition of p53-
dependent apoptosis. The interaction of MIF with p53 was first shown by Hudson et al. in 
1999 (Hudson et al., 1999). They demonstrated the abolishment of p53 activity by treating 
the cells with MIF: Investigations on the MIF knockout mouse model (Fingerle-Rowson et 
al., 2003) showed p53-dependent growth alterations in fibroblasts.  
Evidence of MIF being involved in cell cycle regulation showed an involvement via the 
SCF complex. MIF co-regulates the activity of the skip-cullin-F-box protein complex (SCF 
complex) by inhibition of Jab-1 and might affect proteasomal control of intracellular 
protein degradation (Fingerle-Rowson and Petrenko 2007; Nemajerova et al., 2007). 
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3.1.6 MIF and p53 
Regulation of cell proliferation is necessary for normal cell development and 
prevention of malignant transformation. DNA damage, due to oxidative stress, ionizing or 
ultraviolet irradiation or mutagenic substances enhances the rate of tumor development 
(Rich et al., 2000). To ensure efficient DNA repair in the cell before mitosis, the cell has 
developed p53-dependent and p53-independent checkpoint pathways which delay cell 
cycle progression if the genome is not intact. The p53 tumor-suppressor has at least two 
roles in preventing proliferation of the cell: induction of cell cycle arrest and induction of 
apoptosis (Attardi et al., 1996).  
In earlier studies, MIF has been implicated to play a role in the regulation of cell growth 
and apoptosis (Wistow et al., 1993; Kobayashi et al., 1999). The expression levels of MIF 
alter during growth arrest (Fingerle-Rowson et al., 2003) and can be correlated with tumor 
grading and clinical prognosis in several human cancers (Meyer-Siegler and Hudson 1996; 
del Vecchio et al., 2000; Meyer-Siegler 2000; Markert et al., 2001; Tomiyasu et al., 2002). 
In 1999, MIF was found as a functional inhibitor of p53-dependent transcription in several 
cell-based genetic screens (Hudson et al., 1999). This proposed interaction was 
subsequently confirmed by in vivo studies with MIF knockout mice which showed that 
genetic deletion of MIF enhances p53-dependent activation of the p53 target p21CIP and 
inhibited malignant transformation in vitro as well as tumor formation in vivo (Fingerle-
Rowson et al., 2003).  
The proinflammatory action of MIF together with its inhibitory role in the p53 pathway has 
led to the concept that MIF may act as a molecular link between inflammation and 
tumorigenesis. MIF at sites of chronic inflammation may impair the normal response to 
genetic damage, enhances cell proliferation and promotes the accumulation of oncogenic 
mutations (Cordon-Cardo and Prives 1999).  
 
3.2 Chronic Lymphocytic Leukemia (CLL) 
Chronic lymphocytic leukemia (CLL) is a malignant disease of B cells which is 
characterized by the accumulation of CD5+ B lymphocytes in the peripheral blood, bone 
marrow and secondary lymphoid organs (Harris et al., 1994; Rozman and Montserrat 1995; 
Chiorazzi et al., 2005; Chiorazzi et al., 2005)  
CLL is the most frequent leukemia in the western world, representing about 25 to 30 % of 
all leukemias. It is more common in men than in females, with a sex ratio of 1.5 – 2 : 1 
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(Rozman and Montserrat 1995). The occurrence of CLL is not due to any known 
environmental factors such as ionizing radiation or chemical compounds. Most cases 
appear sporadically and only 5 % of CLL are known to be familial (Houlston et al., 2003).  
 
3.2.1 Biology and Pathogenesis of CLL 
The morphological analysis of CLL blood smears shows an accumulation of small 
mature lymphocytes. The membrane of these lymphocytes is more fragile than normally 
and this leads to the typical picture of smudge cells in peripheral blood smears (Matutes 
and Polliack 2000). 
Immunophenotype analysis is necessary to establish the diagnosis of CLL. Its phenotype is 
very distinctive with leukemic B cells expressing mature B cell markers as CD19, low 
levels of CD20 and high levels of CD5 together with the expression of CD23 which helps 
to distinguish it from other CD5+ malignancies. CLL lymphocytes typically express low 
levels of surface immunoglobulin, most frequently IgM (Matutes et al., 1994; Moreau et 
al., 1997).  
Most of the CLL cells are arrested in the G0 phase of the cell cycle (O'Brien et al., 1995; 
Korsmeyer 1999). Only little is known about the control mechanism, but a recent work on 
lymphocytes suggests that the G0 state represents an active program that requires signals 
from the outside of the cells (Takeda et al., 1996; Lam et al., 1997; Rooke et al., 1997) 
phenomenon of the resting B cells needs further investigations for the analysis of the CLL 
pathogenesis.  
CLL cells carry different genomic aberrations which are seen by conventional cytogenetics 
and fluorescence in situ-hybridization (FISH). Abnormalities can be found in up to 82 % of 
patients with CLL. In 18 %, no genetic abnormalities are found, but still these cases may 
carry submicroscopic aberrations (Dohner et al., 2000).The most frequent chromosomal 
abnormalities are listed in the table 1. 
Chromosome Aberration Frequency Genes affected Prognosis 
13 del 13q14 55% miR15, miR16 good 
11 del 11q22-23 18% ATM,  poor 
17 del 17p13 7% p53 poor 
12 +12 16% CDK2, CDK4,  poor 
   MDM-2  
6 del 6q 5 % unknown poor 
14 t(14;19)(q32;q13) 10 % unknown  
Table 1: Prognostic values of the different chromosomal aberrations.  
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Some of those abnormalities can occur alone or in combination, e.g. structural changes on 
chromosomes 11, 13 and 14 may occur together with deletions and translocations on 
chromosome 13q14 (Juliusson and Gahrton 1990; Juliusson et al., 1990; Dohner et al., 
1999). Using conventional cytogenetic analysis, studies identified trisomy 12, 11q-deletion 
(11q-) and 17p-deletion (17p-) as markers of poor prognosis, whereas other patients with 
normal karyotype or 13q-deletion (13q-) had a better survival (Crossen 1997; Garcia-
Marco et al., 1997; Dohner et al., 1999).  
CLL cells express the B cell receptor (BCR) on the cell surface, as mature B lymphocytes 
do. The BCR is encoded by the immunoglobulin (Ig) genes which undergo somatic 
hypermutation during B cell differentiation in the germinal follicle in order to increase 
BCR affinity for the antigens. Sequencing of the variable genes of the heavy chain locus 
(IgVH) allows therefore telling whether a B cell has undergone somatic hypermutation. The 
mutated form of the B-CLL carries in those cases a good prognostic value for the disease 
while the unmutated form is associated with progressive disease (Damle et al., 1999; 
Hamblin et al., 1999). 
 
3.2.2 Staging 
Two staging systems are currently used to define disease stage, prognosis and 
especially whether and when to start treatment, the Rai staging and the Binet staging 
system. In Europe, the Binet staging system is used which is based on the number of 
lymphoid sites involved and hematopoietic parameters (hemoglobin (Hgb) and platelet 
(Plts)) (Binet et al., 1981): 
(1) Stage A: includes patients with Hgb > 10 g/dL, Plts > 100.000 mm-3 and up to 
two lymphatic sites involved 
(2) Stage B: includes patients with Hgb > 10 g/dL, Plts > 100.000 mm-3 and more 
than two lymphatic sites involved 
(3) Stage C: includes patients with compromised bone marrow function  
(Hgb < 10 g/dL and/or Plts < 100.000 mm-3) regardless the number of 
lymphatic sites involved. 
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3.2.3 Prognosis 
From a clinicians perspective, CLL is known to be a very heterogenous disease. The 
survival of the patients after the first diagnosis ranges from months to decades, with a 
median of 7.5 years (Dighiero and Binet 2000). Therefore, when the diagnosis is CLL, it is 
important to determine the patient’s individual risk for progression.  
There are three traditional prognostic factors which are easily determined: The clinical 
stage according to Binet or Rai in which low stage patients have a better prognosis 
(Cheson et al., 1996). The lymphocyte doubling time indicates disease progression if it is  
< 6 months (Montillo et al., 2005). The third parameter is bone marrow infiltration which 
indicates a poorer prognosis with diffuse infiltration than with nodular infiltration (Molica 
et al., 1990; Mauro et al., 1994; Montserrat et al., 1996).  
On the other hand there are biological prognostic factors which are indicators for the 
extension of the malignant clone (Melo et al., 1986; Melo et al., 1986; Melo et al., 1986). If 
the percentage of prolymphocytes in the peripheral blood exceeds 10 %, it implies a worse 
prognosis for the patient. On the other hand, serum thymidine kinase (TK) levels, a cellular 
enzyme involved in a salvage pathway for DNA synthesis, correlates with survival (Hallek 
et al., 1999; Dickinson et al., 2006). Another serum marker is the β2-microtubulin (β2M)-
level which inversely correlates with the response to chemotherapy and overall survival 
(Keating 1999). Soluble CD23 (sCD23) is a powerful predictor of disease activity and 
progression (Reinisch et al., 1994; Sarfati et al., 1996; Molica et al., 1999; Saka et al., 
2006). sCD23 level can be used as predictor for clinical outcome, particularly in early 
stages (Molica et al., 1996; Schwarzmeier et al., 2002). p53, a transcription factor, known 
to act as tumor suppressor and regulator of the cell cycle, is another prognostic marker of 
CLL. Its inactivation (17p-) correlates with the transformation of CLL to an aggressive 
lymphoma, the so-called Richter’s transformation (Gaidano et al., 1991). 
At the end of the last millennium, new biological markers have been identified, that allow 
a more precise risk-stratification of CLL patients already at the moment of the initial 
diagnosis.  
IgVH mutation is one of those new prognostic markers. Unmutated CLL cases (meaning    
≥ 98 % similarity to the corresponding germline sequence) are associated with an 
aggressive disease and a shorter median survival time (~ 8 years vs. 24 years) as compared 
to mutated cases (Damle et al., 1999; Hamblin et al., 1999). CD38 expression on CLL cells 
was first considered to be a surrogate marker for the mutational status, but studies 
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confirmed CD38 to have an independent prognostic value (Damle et al., 1999). ZAP-70 
was initially considered to be expressed by T and natural killer (NK) cells, but it was also 
found to correlate with the clinical prognosis. An expansion of the ZAP70-positive cells to 
more than 20 % of the leukemic cells carries a negative prognosis (Crespo et al., 2003; 
Wiestner et al., 2003). 
Chromosomal abnormalities are the most important prognostic parameters (Dohner et al., 
1999). Single chromosomal aberrations are quite characteristic for CLL, but they also 
occur in combination expecially during the clonal evolution of the disease (see also table 
1). The most frequent aberration is the deletion 13q- which implies the best prognosis for 
the CLL patients. Deletions of chromosomes 11q and 17p confer much shortened median 
survival. Some of these abnormalities may already be present at the time of diagnosis, 
others (e.g. 17p and 11q) may occur during the progression of the disease and especially 
after chemotherapy. 
 
3.2.4 Current therapy and treatment  
Today there are different treatment options ranging from single-agent treatment over 
combinatorial chemotherapy to the use of monoclonal antibodies in combination with 
chemotherapy (immunochemotherapy). Until today, unfortunately these therapies do not 
cure CLL, only the use of hematopoietic stem cell transplantation can result in complete 
and durable remission of the leukemia.  
Prior to the year 2000, single-agent treatment was based on alkylating reagents such as 
chlorambucil, alone or together with corticosteroids. Most of the patients eventually 
relapsed, and the complete remission (CR) rate was below 10 %. The use of a 
combinatorial chemotherapy (e.g CHOP (cyclophosphamide, doxorubicine, vincrisitine, 
originally known as Oncovine and prednisolone) regimen) resulted in higher response 
rates, but toxicity also increased and it remained unclear whether patients had a benefit in 
terms of overall survival.  
The advent of purine analogs, such as fludarabine, brought a clear improvement in therapy, 
reaching at least a CR rate of approximately 15 % with a significant improvement of 
progression-free survival (Rai et al., 2000). Combination of fludarabine with 
cyclophosphamide, the FC regimen (Eichhorst et al., 2006) and recently with the anti-
CD20 antibody Rituximab, the FCR regimen (Hallek et al. 2008, ASH abstract) achieved 
an impressive increase of CR rates to almost 60 %. Alemtuzumab, a humanized antibody 
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against CD52, which is expressed on all human lymphocytes, monocytes and 
macrophages, is another antibody successfully used for the treatment of refractory CLL 
patients. 
The concept of high-dose chemotherapy supported by autologous stem cell transplantation 
has produced also high remission rates, but given the increased toxicity and risk, the 
benefit in terms of progression-free survival was too little and the long-term side effects 
(secondary cancers, compromise of bone marrow function) too frequent to support this 
concept any longer, especially since no definitive cure can be reached (Pavletic et al., 
1998; Sutton et al., 1998).  
Therefore, allogenic hematopoietic stem cell transplantation is the only therapy offering a 
potential cure of the disease (Michallet et al., 1996; Rondon et al., 1996; Doney et al., 
2002; Moreno et al., 2005). But this comes at a substantial risk of mortality from infection 
and relapse. 
 
3.3 T cell leukemia-1 (TCL1) 
The T cell leukemia-1 family of oncoproteins was first discovered because of its 
involvement in characteristic chromosomal rearrangements in mature T-cell tumors. Those 
translocations and inversions juxtaposed in the coding regions at 14q32 or Xq28. They 
interact with the T cell receptor (TCR) at 14q11 or 7q35. There are three human members 
of the family, mature T-cell proliferation 1 (MTCP1), TCL1 (also called TCL1A) and 
TCL1B (also known as TML1) (Stern et al., 1993; Virgilio et al., 1994; Pekarsky et al., 
1999; Sugimoto et al., 1999). In the mouse Mtcp1 and Tcl1 were identified by homology to 
human TCL1 (Madani et al., 1996; Narducci et al., 1997) and five additional mouse genes 
(Tcl1b1, Tcl1b2, Tcl1b3, Tcl1b4 and Tcl1b5) were cloned by their homology to the human 
TCL1B (Hallas et al., 1999).  
 
3.3.1 Expression pattern of TCL1 
TCL1-family genes in mice are mainly expressed during early embryogenesis, in fetal 
and adult tissues and precursor lymphocytes. Tcl1 is also expressed during B-cell 
development from the pro-B cell through germinal center B cells and also in T-cell 
development, mainly in CD4-CD8- and CD4+CD8+ thymocytes (Narducci et al., 1997; 
Kang et al., 2005).  
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During human embryogenesis, the expression of TCL1 family genes has not been 
evaluated. It is known that TCL1A expression begins in pre-B cells, is downregulated in 
germinal center B cells and silenced in memory B and plasma cells (Virgilio et al., 1994; 
Teitell et al., 1999; Muschen et al., 2002). In T-cell development, TCL1A is only 
expressed in early T cells before the appearance of the surface T cell receptor (Narducci et 
al., 1997; Hoyer et al., 2005). Other, non-lymphatic tissues do not express TCL1, with the 
exception of ovaries (Virgilio et al., 1994). 
 
3.3.2 Organization of the TCL1 gene locus 
The TCL1 family of genes span between 4 and 8 exons and transcribe mRNAs which 
have a length of 1.2 to 2.0 kb. They are located on chromosome 14q32 and on Xq28 in 
humans. In mice, the Tcl1 genes are located on chromosome 12 and the X chromosome.  
It is known that rearrangements of the TCL1-gene locus are associated with T-cell 
leukemias of the mature phenotype, e.g. T-cell prolymphocytic leukemia (T-PLL) (Taylor 
et al., 1996), adult T-cell leukemia (ATL) (Narducci et al., 1997) and with T-cell 
leukemias that develop in patients with the Ataxia telangiectasia syndrome (AT) (Brito-
Babapulle and Catovsky 1991). In most cases, the TCL1 locus on chromosome 14q32.1 
rearranges with the T-cell receptor (TCR) α/δ locus on chromosome 14q11 (Russo et al., 
1989; Virgilio et al., 1993). These rearrangements are either reciprocal translocations or 
inversions. By chromosomal aberrations, the TCL1 oncogene is placed under aberrant 
enhancer/promoter stimulation which leads to its overexpression.  
Introduction of the human TCL1 cDNA under the control of the lck promoter leads to 
transgenic mice developing premalignant T-cell proliferations (Virgilio et al., 1998). 
Pekarsky et al. could show that TCL1 is a real oncogene and that the deregulation of TCL1 
initiates the process of malignant transformation (Pekarsky et al., 2001).  
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Figure 4: Genomic organization of the human TCL1 gene locus (modified from(Pekarsky et al., 
2001). 
3.3.3 Structure of the TCL1 protein 
The TCL1 family proteins range in size from 13 to 15 kDa with a moderate sequence 
conservation between the family members (Fu et al., 1994). The proteins are non-
enzymatic and their structures, expression patterns and subcellular locations dictate their 
physiological and tumorigenic properties. Murine Tcl1 and human TCL1A show a tightly 
packed internal hydrophobic core and share a novel β-barrel structure which includes two 
four-stranded β-chain sheets connected by a long looping strand (Fu et al., 1998; Hoh et 
al., 1998; Petock et al., 2001). Purification studies of human TCL1 provide evidence for 
dimerization (Hoh et al. 1998, structure).  
 
 
Figure 5: The TCL1 oncoprotein as a homodimer.  
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3.3.4 Functional aspects of TCL1 
TCL1 interacts with the N-terminal pleckstrin homology (PH) domain of the 
serine/threonine kinase Akt (Laine et al., 2000; Pekarsky et al., 2000). Like TCL1, Akt 
belongs to a multiprotein family that includes Akt1, Akt2 and Akt3 (also called PKBα, 
PKBβ and PKBγ) (Bellacosa et al., 1991; Datta et al., 1999; Brazil and Hemmings 2001). 
Akt activation is initiated by the binding of an appropriate growth- or survival-stimulating 
ligand to the cell surface receptor, e.g. epidermal growth factor (EGF) to EGF receptor or 
stimulation of the BCR by soluble antigens. The bound cell surface receptor recruits a 
receptor tyrosine kinase which triggers phosphatidylinositol 3-kinase (PI3K) activation at 
the membrane which produces the Akt docking phospholipids. Akt is recruited to the inner 
leaflet of the cytoplasmic membrane, facilitating the assembly of a signaling complex. Akt 
needs its PH domain for membrane relocalization and direct binding to the docking 
phospholipids and activation by phosphorylation. (Burgering and Coffer 1995; 
Delcommenne et al., 1998; Chan et al., 1999; Auguin et al., 2004; Bayascas and Alessi 
2005). Studies showed that Akt is able to cause T-cell lymphoma in mice (Staal et al., 
1977). 
In yeast-two hybrid screens Laine et al. found that all TCL1 isoforms bind to the PH 
domain of Akt. Substrate phosphorylation and the kinase activity of Akt are enhanced by 
the binding of TCL1 which induces conformational changes of Akt within an oligomeric 
TCL1-Akt protein complex (Laine et al., 2000). Akt plays a central role in cell survival and 
proliferation. As TCL1 is located in the cytoplasm as well as in the nucleus (Pekarsky et 
al., 2000) it can promote the nuclear transition of Akt (Pekarsky et al., 2001) which is 
normally located in the cytoplasm (Chan et al., 1999).  
 
3.3.5 TCL1 in Chronic Lymphocytic Leukemia 
As it is known that TCL1 is highly expressed in most B-cell tumors, the TCL1 levels in 
CLL were analysed by immunohistochemical stainings, western blotting and flow 
cytometry (Herling et al., 2006). TCL1 is not uniformly expressed, but appears to be only 
upregulated in a subset of CLL patients. Herling et al. found a correlation between high 
TCL1 levels and the subset of CLL which is characterized by an unmutated VH gene status 
as well as high ZAP-70 expression. Low levels of TCL1 were found in actively 
proliferating centers of the tumor components (Herling et al., 2006). 
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3.3.6 The TCL1 mouse model 
Research in CLL was limited by the lack of a suitable mouse model for CLL until 2002 
when an American group overexpressed human TCL1 in B cells of mice and found that 
these mice developed a lymphoproliferative disease very reminiscent of CLL. The TCL1 
mouse model was further investigated by several independent groups and found to be a 
valuable model for the analysis of CLL pathogenesis.  
In these mice, a 350 bp fragment of the human TCL1 coding region is expressed under the 
control of a mouse IgVH promoter and the Eµ enhancer whose activity specially targets 
immature and mature B cells. The animals were bred on a B6C3 background (a cross 
between a female C57Bl/6NCrl mouse and a male C3H/HeNCrl mouse).  
 
Figure 6: Transgenic construct used to generate the TCL1 transgenic mouse. The human TCL1 
gene is expressed under the control of the B cell specific Eµ-enhancer and the IgVH promoter.  
 
These animals spontaneously develop B cell hyperplasia, initially in the peritoneal cavity 
and then in lymph nodes, spleen, bone marrow and blood, resulting in a massive B cell 
clonal expansion (Bichi et al., 2002). Accumulation of CD5-positive B cells leads to 
enlarged spleens, livers and lymph nodes along with high blood lymphocyte counts.  
Analysis of the IgVL and IgVH genes show no significant somatic hypermutation, 
indicating that the molecular features of the B cell receptor of the transgenic mice resemble 
those from human CLL patients with the unmutated and more aggressive form of CLL 
(Yan et al., 2006). The model has also been successfully used for the analysis of new 
therapeutic drugs for the treatment of human CLL (Johnson et al., 2006).  
 
3.4 Aim of the Work 
MIF is a potential molecular link between inflammation and tumorigenesis. In the 
pathogenesis of CLL, the microenvironment plays a prominent role since the disease 
would not exist without continuous protection of the CLL cells by pro-survival signals 
from the micromilieu. In this work we would like to analyse the role of MIF in the 
pathogenesis of CLL. 
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To understand the relevance of MIF for the pathogenesis of CLL, we used the above 
described Eµ-TCL1 mouse model for human CLL (Bichi et al., 2002). We have crossed 
the Eµ-TCL-1-transgenic mouse model with MIF knockout (MIF-/-) mice. TCL1+/wt MIF-/- 
and TCL1+/wt MIF+/+ mice were compared with respect to leukemia development, tumor 
burden, cytogenetic aberrations and survival. Further studies should reveal the mechanism 
by which MIF affects CLL pathogenesis.  
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4 Results 
4.1 Macrophage Migration Inhibitory Factor (MIF) is overexpressed in 
malignant B cells and human chronic lymphocytic leukemia (CLL) 
Macrophage Migration Inhibitory Factor (MIF) is a known mediator in inflammatory 
diseases. It is known to have an influence in the innate immune system (Denkinger et al., 
2004). In infections, like e.g. sepsis or malaria, MIF is rapidly released by the immune 
cells and has autocrine and paracrine effects promoting cell growth and survival (Calandra 
and Roger 2003). In contrast to MIF acting as a cytokine, MIF secretion is also induced 
due to glucocorticoid hormones (Calandra and Bucala 1995). MIF’s role in the adaptive 
immune system is still under investigation, though it is known that MIF is released by 
activated lymphocytes. Possibly acting through an autocrine loop, MIF is known to 
activate T lymphocytes and to support their proliferation (Bacher et al., 1996).  
Research into the biological mechanisms of MIF action have resulted in several 
possibilities how MIF could influence and regulate cellular growth, differentiation, 
malignant transformation or apoptosis ((Takahashi et al., 1998; Chesney et al., 1999; Yang 
et al., 2000; Mitchell et al., 2002; White et al., 2003). In different cancer entities like 
metastatic prostate cancer or breast carcinoma, MIF expression is upregulated. Different 
studies described its involvement in the development of lymphomas as well as tumor-
associated angiogenesis (Chesney et al., 1999; Nishihira 2000). As inflammation is a 
critical risk factor for tumor development (Karin et al., 2006), MIF is potentially one link 
between chronic inflammation and tumor formation or tumor progression (Hardman et al., 
2005; Bucala and Donnelly 2007). The MIF expression levels seem to correlate with the 
tumor aggressiveness (here tested in human melanoma) and also with its metastatic 
potential (Shimizu et al., 1999). 
In CLL, inflammatory processes play an important role since the disease has features of 
one that is driven by antigenic stimuli (Ghia et al., 2008). Also, survival of the leukemic 
clone crucially depends on environmental stimuli provided by cytokines, chemokines, 
angiogenic factors or the extracellular matrix since the leukemic cells spontaneously 
become apoptotic when the micromilieu is taken away (Burger et al., 2000).  
To investige whether MIF protein expression is upregulated in human CLL, we selected  
10 patients with CLL and a white blood count (WBC) > 50 G/l. The protein content of 
Ficoll-isolated peripheral blood mononuclear cells (PBMC’s) of these CLL patients was 
compared with the protein content of sorted CD19+ B cells from the peripheral blood of  
Results 
_________________________________________________________________________ 
23 
10 healthy donors. In CLL patients, by densitometric analysis MIF was found to be 
upregulated approximately four-fold compared to healthy B cells. A representative 
example of this analysis is given in Fig. 7.  
 
Figure 7: MIF protein is overexpressed in human B-CLL. Representative western blot analysis 
of MIF protein expression in human CLL PBMC’s in comparison to sorted CD19+ B cells of a 
healthy control. MIF is 4-fold upregulated in CLL patient samples. 50 µg of protein were loaded 
onto the gel, membrane was incubated o/n with anti-MIF antibody (dilution 1:1000). β-Actin 
(1:3000) was used as loading control.  
 
In order to find out whether overexpression of MIF contributes to the development of CLL 
or has only bystander significance, we took advantage of the Eµ-TCL1 transgenic mouse 
(Bichi et al., 2002) to analyse the role of MIF in the pathogenesis of CLL in vivo.  
 
4.2 Characterization of the Eµ-TCL1 model for murine CLL 
The Eµ-TCL1 mouse model (Bichi et al., 2002) expresses a 350 bp fragment 
containing the entire coding region of the human TCL1 gene under the Eµ-enhancer and an 
IgVH promoter. The animals were generated on a B6C3H mixed background. The resulting 
phenotype of TCL1 overexpression is a lymphoproliferative disease which arises after 8 to 
15 months of age and strongly resembles human CLL. Later investigations showed that 
this CLL is of the unmutated form, thus representing more or less the more aggressive 
form of human CLL (Yan et al., 2006).  
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Figure 8: Appearance of a TCL1+/+ mouse at the age of 10 months. This mouse shows a distended 
abdomen due to hepatosplenomegaly and the fur is scrubby. At this stage of disease the animals are 
still active and agile. When the disease progresses and the general performance of the mice declines 
and they need to be euthanized.  
 
With increasing age, the animals show clear signs of disease which are manifested by 
scrubby fur, increase in size of the abdomen due to splenomegaly and a reduction in the 
general performance. Macroscopic examination of euthanized mice at an advanced disease 
stage shows enlarged lymphoid organs (spleen, liver and lymph nodes) (Fig. 8). Some 
animals also developed ascites, an accumulation of fluid in the peritoneal cavity.  
 
Figure 9: Example of a leukemic splenomegaly in a TCL1+/+ mouse in comparison to the normal 
spleen size in a C57Bl/6 wildtype control mouse. Both animals were sacrificed at the age of  
12 months. The spleen of the TCL1+/+ mouse has a weight of 4.25 g whereas the spleen of the 
wildtype animal only weighs 0.25 g.  
 
To determine whether the disease is really a B cell lymphoma, lymphoid organs such as 
spleen, lymph nodes, liver and bone marrow were collected and fixed in 4 % formalin 
solution. After 1 week of fixation, the organs were processed and embedded into paraffin. 
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Sections of 3 µm width were cut and stained with Giemsa. Furthermore, staining for the 
CLL marker CD5 and the B cell marker CD79a were done in cooperation with PD Dr.  
H. Kvasnicka at the Institute of Pathology, Cologne University.  
 
 
Figure 10: TCL1+/+ mice develop a CD5-positive B cell lymphoma. Representative Giemsa 
stain and immunohistochemical staining for CD5 and CD79a in spleen (a) and bone marrow (b) 
from a leukemic TCL1+/+ mouse. The leukemic infiltrates are positive for CD5 and CD79a.  
 
Histopathological examination of the affected spleens showed that the splenic architecture 
was totally destroyed by many small lymphocytes which infiltrated the organ (Fig. 10a). 
These small, mature looking lymphocytes are positive stained by IHC for the B cell marker 
CD79a and CD5. Similar leukemic infiltrates can be found in the liver or in the bone 
marrow (Fig. 10b).  
Next we wanted to know whether the known MIF receptors CD74/CD44 and CXCR2 are 
expressed on B cells in this disease model. Peripheral blood from the tail vein of pre-
leukemic (age 3 months) and leukemic TCL1+/+ mice was incubated with specific 
fluorescence-labelled monoclonal antibodies binding to CD74, CD44 and CXCR2 and the 
surface expression was measured with the use of a FACS Canto flow cytometer.  
As shown in Fig. 11, the MIF receptors are expressed both in pre-leukemic as well as in 
leukemic animals. CD74, the first known high affinity receptor for MIF is expressed at low 
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levels in both groups, but expression is not significantly altered by the development of 
overt leukemia. In contrast, the CD44 receptor, one of the signaling modules for CD74 
activated by MIF is significantly higher on the B cells of the leukemic mice compared to 
the pre-leukemic B cells (25975.8 ± 11072.2 for leukemic vs. 6378.7 ± 1797.3 for pre-
leukemic, p = 0.0003). The chemokine receptor CXCR2 is also expressed in both groups 
and its expression is also significantly elevated on the B cells of the leukemic mice (2275.7 
± 598.2 for leukemic vs. 624.2 ± 337.8 for the pre-leukemic, p = 0.03) (Fig. 11). 
 
Figure 11: Expression of the MIF receptors CD74, CD44 and the chemokine receptor 
CXCR2 in TCL1+/+ mice. Peripheral blood of pre-leukemic and leukemic animals (n = 5 each) 
was analysed by FACS. The CD44 signaling complex is significantly higher expressed in the 
leukemic mice (p = 0.0003) as well as the CXCR2 receptor (p = 0.03). CD74 is expressed to nearly 
the same extend in both groups.  
 
Taken together, these preliminary insights into the Eµ-TCL1 mouse model suggested to us 
that it was a suitable model for the analysis of MIF’s role in CLL pathogenesis.  
 
4.3 Analysis of the role of Macrophage Migration Inhibitory Factor 
(MIF) in the development of murine CLL 
In order to obtain a clear picture of what MIF’s role might be in the pathogenesis of 
CLL we bred the TCL1+/+ transgenic mouse to the MIF-/- mouse which had been generated 
by deleting the entire mif gene using a loxP-Cre based deletion system (Fingerle-Rowson 
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et al., 2003). The MIF-/- animals do not show any developmental abnormalities, are fertile 
and produce litters of normal size. Most importantly, their rate of spontaneous tumor or 
leukemic formation is not elevated compared to normal wildtype littermates (Fingerle-
Rowson, personal communication). 
Breeding of the MIF-/- mouse to the TCL1+/+ transgenic mouse was done in the animal 
facility of the experimental surgery, currently run by the Clinic I of Internal Medicine at 
the University Hospital Cologne. Since a homozygous state of the transgene might cause 
artificial phenotypes, special care in the breeding strategy was taken to avoid a 
homozygous state of TCL1 in the F2 generation. The animals of the F2 generation with the 
genotypes TCL1+/wt MIF-/- and TCL1+/wt MIF+/+where used for the analysis of the leukemic 
development and survival. 
 
Figure 12: Breeding strategy of the TCL1+/+ mouse to the MIF-/- mouse. Animals of the F1 
generation with the genotype TCL1+/wt MIF+/- were bred to animals with the genotype TCL1wt/wt 
MIF+/- to obtain the animals of the F2 generation. The animals with the desired genotypes TCL1+/wt 
MIF+/+ and TCL1+/wt MIF-/- where used for the experiments. 
 
Animals with the genotypes TCL1wt/wt MIF+/+ and TCL1wt/wt MIF-/- from the F2 generation 
are used as controls. The genotypes of the animals were determined by polymerase chain 
reaction (PCR). A piece of tail was taken from each mouse while weaning it from the 
parents. DNA was extracted from the tail tissue and a genomic PCR with mif-gene-specific 
and tcl1-gene-specific primers was run and analysed on an agarose gel.  
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Figure 13: Genotyping of the TCL and MIF status. Gel of a genotyping PCR. Lane 1 shows the 
amplification product of TCL1 specific primers (300 bp), lane 2 the product of the MIF wildtype 
allele (544 bp), and lane 3 the product of the MIF knockout allele (383 bp). In lane 4 the expected 
bands of a MIF heterozygous mouse is given (544 bp and 383 bp). 
 
Figure 14: Schematic view of genotyping strategy for MIF. The wildtype mif gene is 
determined with the specific primers B and C, B binds in exon 3 (product 544 bp). In the knockout, 
the primers A and C bind to the MIF gene, leading to a 383 bp product. 
 
After determination of the correct genotypes, animals were either put into the different 
experimental groups or used as control animals.  
 
4.4 Macrophage Migration Inhibitory Factor receptors are expressed in 
murine CLL 
As I could show before in the pre-leukemic as well as in the leukemic TCL1+/+ mice, 
the MIF receptors CD74 and its signaling complex CD44 and the MIF chemokine receptor 
CXCR2 are expressed. To check whether there is a difference due to the MIF knockout, 
the analysis was repeated for the TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice. Five animals 
of each group were analysed by FACS for their receptor expression. Peripheral blood from 
the tail vein of pre-leukemic animals of both groups was taken for the analysis. The 
animals had the age of 6 months.  
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Figure 15: Expression of the MIF receptors CD74, CD44 and the chemokine receptor 
CXCR2in TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice. Peripheral blood of pre-leukemic animals 
(n = 5 per genotype) was analysed by FACS. The CD44 signaling complex as well as the CXCR2 
receptor are expressed to nearly the same extends in both groups. CD74, the extracellular MIF 
receptor is also expressed in both groups, but it is significantly higher in the MIF-/- animals  
(p = 0.03).  
 
Fig. 15 shows the expression of the different receptors in pre-leukemic TCL1+/wt MIF+/+ 
and TCL1+/wt MIF-/- mice (n = 5 per group). Each receptor is expressed on the surface of 
the blood cells, all of them higher in the TCL1+/wt MIF-/- mice. CD44, the signaling 
complex is expressed highest again in both genotypes. CXCR2 is also expressed in both 
groups, a little bit higher in the TCL1+/wt MIF-/- mice. Only CD74, the MIF receptor is 
significantly higher expressed on the TCL1+/wt MIF-/- mice (90.5 ± 38.1 for MIF+/+ vs. 
286.5 ± 135.2 for the MIF-/- mice, p = 0.03).  
 
4.5 Analysis of the leukemia development 
The analysis of the development of the leukemia in the peripheral blood was done 
from tail vein blood taken in intervals of three months (i.e. months 3, 6, 9 and 12) and 
analyzed for leukocyte numbers, differential blood stain and the presence of CD5+IgM+ 
cells. Fig. 16 shows a representative example of a blood smear from a TCL1+/wt MIF+/+ 
mouse at the age of 9 months with evident lymphocytic leukemia. Most prominent is the 
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strongly increased number of small, mature lymphocytes. Besides those intact cells, many 
cells with ruptured membranes can be seen. These cells, so called smudge cells or 
“Gumprecht’s nuclear shadows” are due to an increased fragility of the cellular membrane, 
however, the cellular rupture occurs only during the preparation of the slides. These 
smudge cells are a diagnostic hallmark of human CLL. 
 
Figure 16: Giemsa stain of a peripheral blood smear of a leukemic TCL1+/wt MIF+/+ mouse. 
There is an accumulation of small lymphocytes with thin cytoplasm and dense nuclei (thick 
arrows). Thin arrows point towards smudge cells (also called “Gumprecht’s nuclear shadows”), the 
characteristic hallmark feature of chronic lymphocytic leukemia. 
 
White blood count (WBC), the red blood cell counts (RBC) and platelet counts (PLT) are 
measured by laser flow cytometry from the tail vein blood of the mice. These parameters 
give a global overview on the state of the hematopoietic system and provide a first hint to 
the potential presence of leukemia.  
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Figure 17: Analysis of the white blood count (WBC) from tail vein blood of TCL1+/wt MIF+/+ 
and TCL1+/wt MIF-/- mice over time. The grey bar shows the normal range of WBC of C57Bl/6 
control animals (between 7.000 and 12.000 cells/µl). Animals of the TCL1+/wt MIF+/+ group 
develop an increased WBC more frequently than TCL1+/wt MIF-/- animals, with a higher median in 
TCL1+/wt MIF+/+ mice. 
 
At the age of 3 months, the animals of the TCL1+/wt MIF+/+ group already show a 
significantly higher WBC (p = 0.049) in comparison to the TCL1+/wt MIF-/- animals, a 
trend which continues during the later time points despite the dying of leukemic animals 
(Fig. 17).  
As the normal range of leukocytes in the mouse is between 7.000 and 12.000 cells/µl of 
blood, we set an arbitrary threshold at 20.000 cells/µl of blood in order to differentiate 
leukemia from non-malignant leukocytosis. Fig. 18 displays the Kaplan-Meier incidence 
curve of TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice developing a leukocyte ccount  
> 20.000/µl. The TCL1+/wt MIF+/+ animals exceeded this threshold approximately three 
months earlier than the TCL1+/wt MIF-/- animals (p = 0.02) (Fig. 18).  
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Figure 18: Kaplan-Meier incidence curve of mice developing a WBC > 20.000 cells/µl. 
TCL1+/wt MIF+/+ (black dots) and TCL1+/wt MIF-/- (white dots) mice which developed peripheral 
leukemia with a WBC > 20.000 cells/µl were counted as events. The TCL1+/wt MIF+/+ mice develop 
the leukemia about 3 months in advance to the TCL1+/wt MIF-/- mice. Statistical significance was 
tested using the logrank test (p = 0.02).  
 
Determination of haemoglobin, red blood counts (RBC) and platelet counts provide key 
parameters of bone marrow function which could be influenced by infiltrating CLL cells. 
Of these, the RBC showed that there was a slight, but progressive decrease in the 
production of red blood cells over time which is most likely due to an increasing bone 
marrow infiltration by CLL cells. Animals develop progressive anemia, however the 
presence of absence of MIF did not influence the degree of anemia in a consistent way 
(Fig. 19). Histological analysis of bone marrow revealed that TCL1-induced leukemia also 
infiltrated the bone marrow (Fig. 26). Platelet counts and hemoglobin showed no 
significant differences between the two genotypes, though here a slight decrease in the 
haemoglobin was seen. The platelets declined at month 12 in both groups, probably due to 
the compromised bone marrow by lymphocyte infiltration (Fig. 20).  
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Figure 19: Red blood count (RBC) in TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice over time. 
Analysis was done on the Sysmex XE-2100. The group of the TCL1+/wt MIF-/- mice develop a 
much severe anemia in contrast to the TCL1+/wt MIF+/+ animals. The grey bar indicates the normal 
RBC count of C57Bl/6 animals which ranges from 8.200.000 to 10.500.000 cells/µl of blood. 
 
 
 
Figure 20: Hemoglobin and platelet analysis in TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice. 
The hemoglobin and the platelet analysis over time shows no differences between the two groups. 
In TCL1+/wt MIF+/+ and TCL1+/wt MIF-/-, hemoglobin goes down in the same way. Also the platelet 
count behaves the same in both groups, it  
 
In addition, we performed an accurate count of the malignant cells by FACS analysis for 
CD5+IgM+ cells. CD5 is normally only expressed on NK cells, but not on B cells. Aberrant 
expression of CD5 on B cells is a pathogenomic feature of human and murine CLL.  
Fig. 21 a - d shows a representative example for each genotype. In the wildtype animals, 
the malignant, CD5+IgM+ clone develops significantly faster than in the knock out animals. 
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This is indicated by the percentage of CD5+IgM+ cells based on the total number of 
lymphocytes. In the TCL1+/wt MIF+/+ animal, the malignant clone in month 3 is about  
4.73 %, growing to 5.41 % in month 6 and 7.13 % in month 9. It expands to 72.86 % at the 
last time point of 12 months of age. 
In contrast, the TCL1+/wt MIF-/- (Fig. 21 e – h) mice show less severe signs of disease, the 
malignant clone is nearly not detectable in the peripheral blood. The clone develops from 
1.49 % of the total lymphocytes in month 3 to 4.39 % in month 6. After 9 months of age 
the mouse still only has a malignant clone of 4.64 % of total lymphocytes which does not 
exceed 5.95 % after 12 months of age. This mouse did not show any signs of disease until 
the age of 18 months, when it finally developed a CLL-like disease (data not shown). 
When mice develop frank leukemia, they show visible signs of disease, like scrubby fur, 
apathy and flat breathing.  
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Figure 21: FACS analysis of the malignant clone (CD5+IgM+ cells). Analysis was performed 
from peripheral tail vein blood after 3 (a, e), 6 (b, f), 9 (c, g) and 12 months of age (d, h). a-d gives 
a representative example from the group of TCL1+/wt MIF+/+ mice, e-h gives an example for 
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TCL1+/wt MIF-/- mice. The figures given indicate the percentage of malignant cells of all 
lymphocytes. 
 
 
 
Figure 22: Summary of the absolute number of the malignant CD5+IgM+ clone. At months  
3 and 6 the difference between the two genotypes is significant (p = 0.002 and p = 0.004).  
 
Fig. 22 shows the summary of the total FACS analysis of n = 40 mice per group for the 
development of the malignant clone. This graph gives the absolute numbers of CD5+IgM+ 
cells in the peripheral blood. At month 3, the malignant clone of both groups is still at very 
low levels, however in the group of the TCL1+/wt MIF+/+ mice some animals with increased 
CD5+IgM+ counts can already be detected. Over the next time points of analysis, the 
number of mice with an expansion of the malignant clone increases and the difference 
between the two genotypes is significant at months 3 and 6 (p = 0.002 and p = 0.004). 
Significance is lost at later time points since the diseased animals die and are no longer 
available for analysis.  
The animals at the age of 12 months were then further analysed for organ weight and 
infiltration as well as functional assays were performed, like apoptosis testing and 
proliferation.  
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4.6 MIF increases leukemia load in murine CLL 
Since our analysis of the peripheral blood of the TCL1+/wt MIF-/- and TCL1+/wt MIF+/+ 
mice had shown that the presence of MIF leads to accelerated and increased leukemia 
development, we next tested whether this observation could also be extended for other 
organs such as liver, spleen and bone marrow. Mice (n = 20 per group) were euthanized at 
the age of 12 months and their organs processed for pathological examination. Spleen, 
liver and enlarged lymph nodes were taken out and weighed. One part of each organ was 
then fixed in 4 % buffered formalin and processed for further hematopahological analysis.  
The weight of spleen, the organ which is typically affected by enlargement in human CLL, 
was also enlarged in the TCL1 mouse model, sometimes to a massive degree with spleens 
reaching the pelvic end of the abdomen. Overall, the spleen showed a clear trend towards 
stronger enlargement in the TCL1+/wt MIF+/+ mice, but due to the relatively low number of 
animals used for this analysis the difference was not quite statistically significant  
(TCL1+/wt MIF+/+ 1.3 g ± 0.8, TCL1+/wt MIF-/- 0.67 g ± 0.5, p = 0.07). On the other hand, 
the liver, an organ which also may be infiltrated and enlarged in humans by CLL, showed a 
significant difference (TCL1+/wt MIF+/+ 3.27 g ± 1.1, TCL1+/wt MIF-/- 1.67 g ± 0.68,  
p = 0.0028) with a higher weight in the MIF+/+ animals. Thus, the presence of MIF leads to 
a clear increase of the leukemic load in murine CLL (Fig. 23).  
 
Figure 23: MIF promotes hepatosplenomegaly in CLL. Analysis of spleen and liver weight of 
TCL1+/wt MIF+/+ (n = 7) and TCL1+/wt MIF-/- (n = 9) mice. The livers of the TCL1+/wt MIF+/+ animals 
were significantly larger than those of the TCL1+/wt MIF-/- animals. Spleens of TCL1+/wt MIF+/+ 
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animals were larger than those of TCL1+/wt MIF-/- animals, but this difference did not quite reach 
statistical significance (p = 0.07). 
 
4.7 Immunohistochemical analysis of the TCL1+/wt MIF+/+ and TCL1+/wt 
MIF-/- animals 
As a next step, we wanted to determine the cellular source of the TCL1-induced 
leukemia. We performed a histopathological screening of the organs and stained the spleen 
and bone marrow for B- (CD79a), T- (CD3) and macrophage- (CD68) cell markers. 
Malignant or normal B cells were differentiated by the use of CD5. 
Fig. 24 provides representative pictures from Giemsa and immunohistochemical staining 
of spleens from TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- animals. The Giemsa stain reveals 
extensive infiltration of the spleen by small, mature looking lymphocytes which clearly 
point the presence of lymphoma. These lymphatic cells are positive by 
immunohistochemistry for CD79a and CD5 which proves that this lymphoma is of the 
CLL phenotype. A T-cell lymphoma could be excluded since these atypical lymphocytes 
were clearly negative for CD3. CD3+ T cells though were also present in the spleens of 
both genotypes and there was no significant difference. Interestingly, staining for CD68, a 
macrophage marker, demonstrates a significantly higher number of macrophages in the 
infiltrated areas of the spleen of TCL1+/wt MIF+/+ animals as compared to TCL1+/wt MIF-/- 
mice (29.4 ± 46.4 vs. 9.7 ± 38.5, p < 0.0001) (Fig. 25). 
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Figure 24: Representative immunohistochemical staining of spleen from a TCL1+/wt MIF+/+ 
mouse (a) and a TCL1+/wt MIF-/- mouse (b). Staining was done for CD5, CD79a, CD3 and CD68. 
Giemsa stain was performed in order to get an overview. The normal structure of red and white 
pulp does no longer exist in these spleens due to extensive infiltration by lymphocytes.  
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Figure 25: Higher number of macrophage infiltration in TCL1+/wt MIF+/+ mice. CD68+ cells 
were counted in the infiltrated regions of the leukemic spleens of TCL1+/wt MIF+/+ mice (n = 18) 
and TCL1+/wt MIF-/- mice (n = 14). TCL1+/wt MIF+/+ mice have a significantly higher number of 
macrophages in the lymphocytic infiltrate compared to the TCL1+/wt MIF-/- mice (p < 0.0001). 
 
The bone marrow was stained in a similar fashion as spleens and livers. The Giemsa stain 
of bone marrow of the TCL1+/wt MIF+/+ mice and the TCL1+/wt MIF+/+ mice also showed 
infiltration by small lymphocytes which uniformly stained positive for CD79a and CD5, 
again confirming the diagnosis of CLL. To further analyse the expression of other cell 
types like T cells and macrophages, staining for CD3 and CD68 were done (Fig. 26).  
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Figure 26: Representative immunohistochemical staining of bone marrow from a TCL1+/wt 
MIF+/+ mouse (a) and a TCL1+/wt MIF-/- mouse (b). Staining was done for CD5, CD79a, CD3 and 
CD68. Giemsa stain was performed in order to get an overview. 
 
4.8 MIF affects overall survival in murine CLL 
Both experimental groups as well as control mice (TCL1+/+, MIF-/-, MIF+/+) were also 
analysed for overall survival. To this end, animals were observed from birth until death, or, 
if the performance status of the mouse was too severely affected (e.g. weight loss > 10 %, 
apathy, swollen abdomen), to the time point at which the animal had to be euthanized. For 
the group of TCL1+/wt MIF+/+ and for the group of TCL1+/wt MIF-/-, we analysed a total of  
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n = 40 mice for each genotype. These mice were also screened for the presence of 
leukemia by a 3-monthly blood examination as described before.  
Mice were analysed for up to 750 days. The median survival for TCL1+/wt MIF+/+ mice is 
380 days, whereas the animals with the genotype TCL1+/wt MIF-/- have a median survival 
of 460 days. The difference of 80 days is significant (p = 0.04) (Fig. 27).  
 
 
Figure 27: Kaplan Meier curve of cumulative survival of TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- 
animals. TCL1+/wt MIF+/+ (filled circles) and TCL1+/wt MIF-/- (empty circles) are observed from 
birth to sudden death or time of euthanization. The median survival of TCL1+/wt MIF+/+ is 380 days, 
whereas the TCL1+/wt MIF-/- animals have a median survival of 460 days. The difference in overall 
survival of 80 days is statistically significant with a p-value of 0.04 by the logrank test.  
 
We also performed a comparison of the experimental groups with their non-TCL1-
transgenic counterparts, i.e. TCL1wt/wt MIF+/+ and TCL1wt/wt MIF-/- (n = 20 per group). As 
expected, TCL1-transgenice animals have significantly shortened survival in comparison 
to their non-transgenic controls (Fig. 28 upper and lower panel). Gene dosage of TCL1 
does not seem to affect the overall survival since we did not observe a significant 
difference between TCL1+/+ and TCL1+/wt MIF+/+ mice (Fig. 28 upper panel). 
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Figure 28: Kaplan-Meier curves of survival for each genotype in comparison to non-
transgenic controls and homozygous TCL1+/+ mice. Upper panel: Overall survival of TCL1 
MIF+/+ mice. Non-transgenic MIF+/+ mice do not develop leukemia and the gene dosage of TCL1 
shows only a little impact in the presence of MIF. Lower panel: Overall survival of TCL1 MIF-/- 
mice. Non-transgenic MIF-/- mice do not develop leukemia.  
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The difference in survival between transgenic and non-transgenic animals is very clear and 
highly significant (TCL1wt/wt MIF+/+ vs. TCL1+/wt MIF+/+ with p = 0.0079 and  
TCL1wt/wt MIF-/- vs. TCL1+/wt MIF-/- with p = 0.00016) (Fig. 28). We did not observe any 
leukemia in those control mice. Occasional deaths were probably due to old age, since 
pathological analysis did not reveal any organ abnormalities (data not shown). 
The gene dosage of TCL1, i.e. a heterozygous or homozygous status of the transgene 
which we could control by the breeding scheme used, did not seem to have a significant 
impact on overall survival in MIF+/+ mice.  
These results confirm that MIF is a relevant regulator of TCL1-driven lymphomagenesis 
and we therefore attempted to elucidate more of the mechanism by which MIF might 
promote murine CLL.  
 
4.9 MIF deficiency lowers the apoptotic threshold 
MIF is known to affect the rate of apoptosis in splenocytes of the Eµ-myc mouse 
model via a p53-dependent mechanism (Talos et al., 2005). We therefore analysed spleens 
from animals of the age of 12 months for spontaneous apoptosis in vivo and tested their 
splenocytes ex vivo for drug-induced apoptosis.  
Paraffin-embedded spleen sections from TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice were 
stained by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling 
(TUNEL) in order to detect the in vivo rate of apoptosis within the spleen. Propidium 
iodide (PI) which is used for the counterstain, colours the permeable membrane of dying or 
dead cells in red.  
Fig. 29 shows a representative example out of n = 5 independent experiments per group for 
the differences in TUNEL-positive apoptotic cells in TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- 
mice (Fig. 29). A counting of the TUNEL positive cells per visual field resulted in a 
significantly higher number of positive cells for the TCL1+/wt MIF-/- spleens compared to 
the TCL1+/wt MIF+/+ spleens (123 ± 28.1 for MIF knockout vs. 51 ± 16.6 for MIF wildtype, 
p < 0.0001) (Fig. 30). The spleens compared here were all taken from leukemic mice.  
We then wanted to further analyse this finding by an ex vivo analysis of splenocytes from 
both leukemic as well as pre-leukemic mice.  
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Figure 29: MIF-deficiency increases spontaneous apoptosis in TCL1-trangenic splenocytes in 
vivo. Representative TUNEL staining of a TCL1+/wt MIF+/+ spleen (a) and a TCL1+/wt MIF-/- spleen 
(b) from n = 5 independent experiments per group. Counterstain was done with propidium iodide 
(PI). Pictures were taken on a confocal microscope. In TCL1+/wt MIF+/+ splenocytes, the rate of 
TUNEL positive apoptosis is greatly enhanced compared to TCL1+/wt MIF-/- splenocytes. The 
pictures are taken at 600-fold magnification.  
 
 
Figure 30: A higher rate of TUNEL positive cells in the TCL1+/wt MIF-/- spleens. Counting of 
the TUNEL positive cells per visual field at a 6 00-fold magnification. In the TCL1+/wt MIF-/- 
spleens a significantly higher number of apoptotic cells is found in comparison to the TCL1+/wt 
MIF+/+ spleens (p < 0.0001).  
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For in vitro analysis of apoptosis, splenocytes from pre-leukemic (month 3) and leukemic 
mice were treated with cytostatic drugs and with the corticosteroid prednisolone. We used 
chemotherapeutic drugs which are in common use for the therapy of patients with CLL 
nowadays. Fludarabine, a purine analog, inhibits DNA synthesis by interfering with the 
DNA polymerase in the cells and can be regarded as the standard drug of CLL therapy at 
the moment. It acts against resting and dividing cells. Vincristine, an inhibitor of the 
spindle apparatus is used in cancer chemotherapies to disrupt mitosis during the phase of 
chromosome separation and division of the cell into two identical daughter cells. It 
therefore only affects dividing cells. As a third drug, we used prednisolone, a 
glucocorticoid, which is in use for the treatment of lymphatic leukemias and for the 
treatment of inflammatory and auto-immune diseases. To find out whether the apoptotic 
response of MIF-expressing and MIF-deficient splenocytes as altered in our model, we 
tested those three substances on splenocytes of leukemic and pre-leukemic mice from 
TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- animals ex vivo.  
 
 
Figure 31: Drug induced apoptosis ex vivo. Splenocytes of pre-leukemic (a) and leukemic (b) 
mice were harvested from spleens of TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice and treated with 
cytostatic drugs (50µM fludarabine, 50 ng/ml vincristine, 1 µM prednisolone) for 24 h ex vivo. For 
each group and genotype n = 5 animals were analysed. * statistical significance with p = 0.04. 
 
Splenocytes of pre-leukemic (n = 5) and leukemic (n = 5) animals of TCL1+/wt MIF+/+ and 
TCL1+/wt MIF-/- mice were treated with fludarabine (50 µM), vincristine (50 ng/ml) and 
prednisolone (1 µM) for 24 h and then analysed for apoptosis.  
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Splenocytes from the pre-leukemic TCL1+/wt MIF-/- mice are more sensitive to the 
induction of apoptosis than the cells from the pre-leukemic TCL1+/wt MIF+/+ mice. Also the 
rate of spontaneous apoptosis (no treatment) is higher in the MIF-deficient cells. In the 
example of the purine analog fludarabine, the apoptotic response is significantly 
pronounced and 72.7 % (± 16.5) of TCL1+/wt MIF-/- cells undergo apoptosis in comparison 
to 44. % (± 1.3) of the cells from the TCL1+/wt MIF+/+ mice (p = 0.04) (Fig. 31 a). 
Prednisolone shows the best effects in the pre-leukemic cells, more than 80 % of the cells 
are dead after 24 h. At an earlier time point (8 h), differences between TCL1+/wt MIF+/+ and 
TCL1+/wt MIF-/- were not apparent (data not shown).  
Interestingly, for the splenocytes of the leukemic TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- 
mice, the response to DNA damage or glucocorticoid stimulation was quite opposite. Here 
cells undergo spontaneous apoptosis of about 64.2 % (± 24.1) in the MIF wildtype cells, 
whereas only 46.5 % (± 7.3) of the MIF knock out cells die after 24 h (Fig. 31 b). This 
observation extends also to unstimulated cells which exhibited reduced spontaneous 
apoptosis in the absence of MIF. Since previous studies had shown that MIF acts as an 
essential regulator of the DNA damage pathway (Nemajerova et al., 2007), we tested two 
different pathway inhibitors. On the one hand, we used NSC-663284, a complete CDC25 
inhibitor. CDC25 phosphatases activate Cyclin-dependent kinases (CDKs) and thereby 
regulate the cell cycle. In mammals there are three CDC25 family members (CDC25A, B 
and C), which collaborate in coordinating timely activation of multiple cyclin/CDKs at 
different phases of the cell (Sadhu et al., 1990; Galaktionov and Beach 1991; Nagata et al., 
1991; Boutros et al., 2007). CDC25A regulates the G1-S transition as well as the transition 
of G2-M (Hoffmann et al., 1994; Busino et al., 2004) making it an essentaial component 
for all phases of the cell cyle. CDC25B and C are essential regulators of the G2-M 
transition (Lammer et al., 1998; Perdiguero and Nebreda 2004). On the other hand we used 
Pifithrin-α, a reversible p53 inhibitor (Komarov et al., 1999) to find out whether the 
difference in the rate of apoptosis was dependent on the p53-pathway. Those two inhibitors 
were used in combination with fludarabine. As a third component we used the therapeutic 
proteasomal inhibitor bortezomib, currently in use for the treatment of multiple myeloma 
and mantle cell lymphoma. Bortezomib binds the 26S proteasome with high affinity and 
inhibits its function by regulating protein expression (e.g. NF-κB) and degradation of 
ubiquitylated proteins. Since intracellular MIF inhibits the metalloprotease c-jun activating 
and binding protein-1 (Jab-1), it co-regulates the activity of the skip-cullin-F-box protein 
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complex (SCF complex) and might affect proteasomal control of intracellular protein 
degradation (Fingerle-Rowson and Petrenko 2007; Nemajerova et al., 2007).  
 
 
Figure 32: Apoptosis induction in pre-leukemic mice. Testing whether the apoptotic effect is 
dependent on either p53 or CDC25 with the inhibitors NSC-663284 (10nM) and PFT-α (10 µM) in 
combination with 50 µM fludarabine. Bortezomib (5 ng/ml), a proteasomal inhibitor shows 
significance after 24h of treatment (p = 0.02).  
 
Treatment of the splenocytes in combination with fludarabine and the CDC25 inhibitor 
NSC-663284 as well as a combination of fludarabine and the p53 inhibitor PFT-α was not 
able to abrogate the difference between the two genotypes. Cells undergoing spontaneous 
or fludarabine-induced apoptosis still show the same differences in the apoptotic rates as 
without these inhibitors. These results indicate that those two pathways tested do not play 
the key role in apoptosis-induction for the MIF+/+ and MIF-/- TCL1+/wt mice. Also the 
proteasomal inhibitor bortezomib did not abrogate the difference in the two genotypes and 
therefore we conclude that MIF’s intracellular activity of regulating the SCF complex is 
not responsible for the observed effects either (Fig. 32).  
Taken together, while the in vivo TUNEL staining yielded clear results, the ex vivo 
experiments were somewhat contradictory within themselves and did not solve the 
question of which pathway might be involved in the increased apoptosis sensitivity of 
TCL1+/wt MIF-/- splenocytes in vivo.  
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4.10 Analysis of cellular proliferation 
Differences in the incidence of leukemia may also reflect differences in the 
proliferative capacity of malignant cell. In order to determine the spontaneous rate of DNA 
synthesis as a surrogate marker for cell cycle entry TCL1+/wt MIF+/+ and TCL1+/wt MIF-/-  
(n = 10 per genotype) were injected with bromo-desoxy-uridine (BrdU) in vivo. BrdU, a 
thymidin analog, intercalates with the DNA during the S-phase of the cell cycle and can be 
detected by anti-BrdU-specific antibodies. It was injected into the peritoneal cavity (i.p.) 
over 4 days at a concentration of 50 µg/kg bodyweight. On day five, the animals were 
killed, splenocytes were taken out and stained for BrdU and further analysed by FACS. We 
measured the percentage of BrdU incorporation into the malignant clone  
(CD5+IgM+ cells). 
In the pre-leukemic (aged 4 months, n = 4 for each genotype) splenocytes, no differences 
in the in vivo BrdU incorporation could be measured. Splenocytes of leukemic  
TCL1+/wt MIF-/- mice (n = 6 for each genotype), however, incorporated more BrdU into the 
DNA of the CD5+IgM+ cells than their wildtype counterparts (13.9 % ± 5.4 for MIF+/+  
vs. 37.4 % ± 19.7 for MIF-/-) (Fig. 33).  
 
Figure 33: BrdU incorporation in splenocytes of pre-leukemic (month 4) and leukemic 
TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice. Although there was a trend towards increased BrdU 
uptake in MIF-deficient splenocytes, this difference was not significant.  
 
To control this result of the in vivo-proliferation, we tested pre-leukemic splenocytes for ex 
vivo proliferation by incorporation of EdU. EdU is a similar component to BrdU, it also 
intercalates the DNA during the S phase and can be measured by flow cytometry. The cells 
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were stimulated with 1 µg/ml of lipopolysaccharid for 24h, which stimulates B cell 
proliferation. After 24 hours, the splenocytes were pulsed with EdU and further incubated 
for another 24 hours. Cells were then stained according to the protocol from Invitrogen 
(Karlsruhe, Germany) and the analysis was done on the FACS Canto. 
In this system, the TCL1+/wt MIF+/+ cells seemed to proliferate more vigorously than the 
TCL1+/wt MIF-/- cells (336.3 ± 188.7 for TCL1+/wt MIF+/+ vs. 71.5 ± 9.2 for TCL1+/wt MIF-/-
, p = 0.13) (Fig. 34).  
 
 
Figure 34: EdU incorporation into splenocytes ex vivo. EdU incorporation in splenocytes from 
pre-leukemic TCL1+/wt MIF+/+ (n = 3) and pre-leukemic TCL1+/wt MIF-/- (n = 3) animals. Cells were 
stimulated with 1 µg/ml LPS for 24 h, followed by a 24 h pulse of 7.5 µg/ml EdU. Cells were then 
fixed, stained and analyzed by FACS. The difference between the two genotypes is not significant 
(p = 0.13).  
 
4.11 Analysis of Metaphase-Chromosomes 
TCL1 itself is a rather weak oncogene which by itself does not induce leukemia, but 
instead induces genomic instability and secondary genomic damage subsequently leading 
to leukemic development. Since MIF has been implicated in the regulation of genome 
protection (Nemajerova et al., 2007), we performed spectral karyotyping (SKY) of 
metaphase chromosomes from purified splenocytes of leukemic animals (TCL1+/wt MIF+/+ 
and TCL1+/wt MIF-/-) in cooperation with the group of Dr. C. Rudolph and Prof. Dr. B. 
Schlegelberger from the Institute for Cellular and Molecular Pathology of the Hannover 
Medical School (MHH).  
Results 
_________________________________________________________________________ 
51 
We were able to analyse n = 3 animals for the TCL1+/wt MIF+/+ and n = 4 animals for the 
TCL1+/wt MIF-/- group. Overall, we observed trisomy, tetraploidy, deletions and 
translocations. The most prominent cytogenetic aberration found in both groups is the 
trisomy 15, manifested in two of three or four mice per genotype (table 2). We did not find 
significant differences in the number of malignant clones or type of the cytogenetic 
aberration between both groups.  
 
Figure 35: Representative example of a SKY-analysis of a TCL1+/wt MIF+/+ mouse. The picture 
displays the karyogram of the analyzed animal. Trisomy 15 was the most prominent aberration 
found throughout both groups.  
 
Probe  Genotype Cytogenetics 
FIN 3558 TCL1+/wt MIF+/+ 41,XY,+15 [6]/ 42-43,XY,+10,+Del(15) [cp5]/ 40,XY [4] 
FIN 3587 TCL1+/wt MIF+/+ 80<4n>,XXYY [8]/ 40,XY [7] 
FIN 3568 TCL1+/wt MIF+/+ 41,XY,+15 [14] 
FIN 3275 TCL1+/wt MIF-/- 40,X,-X,+15 [2]/ 41,XX,+15 [1]/ 40,XX [8] 
FIN 3319 TCL1+/wt MIF-/- 71~75,XXY,-Y,Der(1)T(1;?10), 
Der(4)T(4;?),Der(15)T(7;15),mar [cp9] /40,XY [4]/ 
80<4n>,XXYY [2] 
 
FIN 3317 TCL1+/wt MIF-/- 40,XY [10] 
FIN 3555 TCL1+/wt MIF-/- 40,X,-Y,+15 [9]/ 41,XY,+15 [5] 
Table 2: SKY analysis of metaphase chromosomes from splenocytes of TCL1+/wt MIF+/+ and 
TCL1+/wt MIF-/- mice.  
 
Spectral karyotyping was also done on prepared metaphases of splenocytes from leukemic 
TCL1+/+ mice (table 3). Here we were able to analyse n = 9 animals. As seen in the 
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TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice, the trisomy 15 is a recurrent finding of all 
groups. In the TCL1+/+ mice, it is manifested in nearly 80 %, giving it a large impact on the 
leukemia development. Also the tetraploidy is a frequent finding. The important result of 
the analysis of the homozygous TCL1 mice is the occurrence of even more and partly 
pretty severe genetic aberrations. Those findings need to be further analysed as some of the 
findings have not been described.  
 
Probe  Genotype Cytogenetics 
FIN 1486 TCL1+/+ 41,XY,+X [2]/ 39~42,X,-Y,-1,+6,?T(8;10),Del(8), 
Der(14)T(1;14),+15,+15,Ins(16;?)[cp13] 
FIN 1913 TCL1+/+ 40,XX,-12,+15 [12]/ 80,<4n>,XXXX [3] 
FIN 2142 TCL1+/+ 39~42,XY,Der(8)T(8;18),Del(13),Der(18)T(13;18) or 
T(13;18),+15 [cp10] 
41~42,XY,Del(5),+6,+13,Der(16)T(16;5;16) [cp3] 
40~41,XY,Der(14)T(13;14) [3] 
41~42,XY,Del(5),Der(6)T(6;11;?6;11),-11,+13 [2] 
FIN 2681 TCL1+/+ 41~43,XX,T(2;2),+9,+15,+18,+19 [cp15] 
FIN 3094 TCL1+/+ 41,XY,+15 [6]/80,<4n>,XX,YY [4]/41,XY,+X [1]/40,XY [4] 
FIN 3147 TCL1+/+ 40,XY,Ins(19;16) [15] 
FIN 3190 TCL1+/+ 40-44,X,?Del(X) or Del(5),?Der(2)T(2;5),Der(5)T(5;11), 
Der(11)T(2;11),+14,+15,+15,Der(17)T(16;17),+19 [cp11]/ 
40,X0, T(1;8),+15 [2] /40,XY [1] 
FIN 3267 TCL1+/+ 38-39,XX T(4;9),Del(5),Ins(6;?5),T(6;13),Der(16)T(12;16) 
[cp11]/ 40,XX [4] 
FIN 3836 TCL1+/+ 41,XY,T(12;12),+15 [cp13]/ 40,XX [1]/ 40,XX,Der(17) [1] 
Table 3: SKY analysis of metaphases from leukemic TCL1+/+ mice. A high number of 
chromosomal aberrations is found in these splenocytes. Trisomy 15 and tetraploidy are the most 
prominent ones.  
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4.12 Expression analysis of known tumor regulators in leukemic and 
pre-leukemic mice 
On murine chromosome 15, the proto-oncogene c-myc is known to be located. C-myc 
is an important transcription factor and regulator of cell cycle control (Obaya et al., 1999).  
To further evaluate whether c-myc protein is upregulated in TCL1-induced leukemia, 
western blot analysis of leukemic and pre-leukemic protein-lysates from splenocytes were 
analyzed for c-myc expression in the nuclear extracts. We also wanted to know whether 
other tumor-regulators such as B cell lymphoma-2 (Bcl-2), MDM2 and p53 were 
upregulated or altered in the mice.  
Cytoplasmic and nuclear extracts of splenocytes from pre-leukemic and leukemic  
TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice were done. To determine the protein levels of 
tumor genes and the altered pathways, the protein lysates were separated on a SDS-PAGE 
and analysed by incubation with specific antibodies. As positive control we used Raji cells, 
a cell line derived from Burkitt lymphoma, belonging to the aggressive B cell non-Hodgkin 
lymphomas (lane 1 in the leukemic WB (Fig. 36 a) and the last lane for the pre-leukemic 
(Fig 35 .b) lysates).  
Western analysis of protein lysates from pre-leukemic and leukemic mice showed few 
differences between TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice. For the leukemic mice 
(Fig. 36 a) we could show, that the in the TCL1+/wt MIF-/- mice, the anti-apoptotic protein 
Bcl-2 is upregulated. More interestingly though is the observation that we found a strong 
overexpression of the tumor suppressor p53 in the TCL1+/wt MIF+/+ lysates. 
With respect to c-myc expression, we could not detect any significant differences between 
the genotypes, but we see significant overexpression of c-myc in individual mice which 
needs to be further correlated to the presence of the trisomy 15 in the animals.  
Also in the lysates of the pre-leukemic splenocytes (Fig. 36 b) we see a similar picture 
emerging. Again, we find more Bcl-2 in the TCL1+/wt MIF-/- lysates, and p53 is again 
upregulated in the MIF wildtype mice.  
The observed p53 overexpression is reminiscent of mutated p53 and experiments are 
ongoing to determine the mutational status of p53 in our animals.  
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Figure 36: Western blot analysis of cytoplasmic and nuclear cell lysates of leukemic (a) and pre-
leukemic (b) TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice. MIF (1:1000), Bcl-2 (1:1000),  
MDM2 (1:200) were measured from cytosolic lysates, p53 (1:200), c-myc (1:200) from nuclear 
lysates. p84 (1:1000) served as loading control for nuclear proteins, β-actin (1:3000) as loading 
control for cytosolic proteins. Lane 1 (a) and lane 7 (b) positive control (Raji cell line). 60 µg of 
proteinextracts were loaded onto the gels.  
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5 Discussion 
Chronic lymphocytic leukemia (CLL), the most common leukemia in the Western 
world has remained a non-curable malignant disease which significantly reduces the 
quality of being and the life expectancy of the affected individuals. Thus, the impetus to 
study CLL pathogenesis and to improve therapeutic options remains high in the field of 
CLL research. 
Until 2002, all evidence generated on CLL pathobiology was based on ex vivo analysis of 
CLL cells and clinical evidence from CLL patients. Molecular targets were validated in the 
artificial context of in vitro-culture or in human studies. With the advent of the Eµ-TCL1 
transgenic mouse model for CLL in 2002 (Bichi et al., 2002), CLL researchers obtained a 
new research tool that allows the genetic validation of therapeutic targets before 
proceeding to human phase I/II trials. The TCL1 mouse has also proven useful for the 
testing of new therapeutic drugs (Johnson et al., 2006).  
We were prompted to study the role of Macrophage Migration Inhibitory Factor (MIF) in 
the pathogenesis of the murine CLL since we knew that MIF acts as a functional link 
between inflammation and tumorigenesis and that survival of CLL is strongly dependent 
on the stimulation by chemokines and chemokine receptors (Burger et al., 2000). Although 
the nature of MIF remained uncertain for many years and it was discussed to be a 
hormone, cytokine or enzyme (Swope and Lolis 1999), more and more evidence emerges 
that MIF functions as an extracellular chemokine-like molecule which binds to the surface 
receptors CD74/CD44 and CXCR2 (Bernhagen et al., 2007). Both these surface receptors 
are known to be involved in leukemogenesis/lymphomagenesis, but have not been studied 
in the context of CLL. 
Taken together, our results show that MIF acts as a relevant promoter of CLL 
development. Specifically, MIF shortens the pre-leukemic phase and increases the 
incidence of leukemia, promotes organ infiltration by the malignant cells and increases the 
tumor load. Acceleration of disease by MIF is substantial since it shortens overall survival 
of mice by 80 days. This amounts to about 8 % of a mouse’s life time of approximately 
1000 days (ref. Jackson labs for mouse life span). To our knowledge MIF is the first target 
molecule for which a survival effect has been shown. Given the almost ubiquitous 
expression of MIF and its many known effects on proliferation, apoptosis, differentiation 
or malignant transformation, the big question in this project was to elucidate the 
mechanism by which MIF promoted leukemia development.  
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5.1 MIF promotes the accumulation of CD68+ macrophages 
It has been shown that the expansion and survival of CLL cells depends on the 
presence of “nurse-like” cells (NLCs) that seem to be monocyte-derived components of the 
marrow stroma (Burger et al., 2000; Tsukada et al., 2002). NLCs express cytoplasmic 
vimentin and stromal-derived factor 1 (SDF-1) and SDF-1 is known to interact with 
CXCR4, one of the MIF chemokine receptors (Amara et al., 1999; Mohle et al., 1999). 
Despite expressing antigens in common with blood monocytes, monocyte-derived 
dendritic cells, and macrophages, NLCs expressed significantly higher levels of CD68 than 
some of these other cell types.  
In the immunohistochemical staining of infiltrated organs, T- and B-lymphocyte 
infiltrations were found in both groups of mice, but the number of macrophages is 
significantly reduced in the infiltrated areas of the spleen and bone marrow in the absence 
of MIF. Also in the non-infiltrated areas of these organs, the number of macrophages is 
reduced. This effect is not entirely novel, since it was described before, that MIF acts as a 
survival factor for macrophages during stress (Mitchell et al., 2002). It is further known 
that MIF blockade inhibits the accumulation of CD68+ cells (Schober et al., 2004; Burger-
Kentischer et al., 2006). In addition to that, the production of MIF by bone marrow 
residing dendritic cells was recently shown to be essential for the presence of mature B-
cells in the bone marrow of mice (Sapoznikov et al., 2008). 
Macrophages produce a number of cytokines and substances which may promote the 
survival of B cells. This process is mediated by a number of cytokines, e.g. tumor necrosis 
factor-α or interleukin-1 and on the other hand mediated by a variety of chemokines and 
cell adhesion molecules.  
The CLL-like disease in our model expresses the MIF receptors CD74/CD44 and CXCR2, 
all of which are highly relevant for leukemogenesis and survival of malignant cells. The 
expression of CD44 and CXCR2 was even upregulated in the malignant CD5+IgM+ cells 
compared to non-malignant IgM+ cells.  
CD74 is expressed on B cells and directly involved in the survival of the mature B cell 
population (Shachar and Flavell 1996; Matza et al., 2002; Matza et al., 2003). CD44, a co-
receptor of the CD74 receptor complex, is highly upregulated in the leukemic mice, and 
CD44 surface expression in human CLL is known to be correlated with a significantly 
poorer survival (De Rossi et al., 1993; De Rossi et al., 1994). Recently, colleagues of mine 
could show that CD44 acts as a survival favtor for CLL cells in culture by activating CD44 
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with its ligands hyaloronic acid and chondroitin sulphate (Peer Zada et al., manuscript in 
preparation).  
The chemokine receptor CXCR2, a leukocyte-specific receptor of MIF, is also 
significantly upregulated in the leukemic mice and is known to play a central role in 
macrophage accumulation in atherosclerosis and the progression of the atherosclerotic 
lesions (Boisvert et al., 2006).  
CXCR2 has several ligands, a prominent one being interleukin-8 (IL-8) which has been 
identified as a component of the signaling cascade triggered by activated CD74 which 
leads to apoptosis resistance in human CLL (Binsky et al., 2007; Gore et al., 2008). 
Binding of MIF to CXCR2 recruits leukocytes to the inflammatory sites of atherosclerosis 
and targets monocytes and neutrophils (Bernhagen et al., 2007; Dewor et al., 2007). 
In analogy to these effects, it is conceivable that CXCR2 or CD74/CD44 also contribute to 
the accumulation of nurse-like cells in our model in the presence of MIF. Further genetic 
studies are ongoing in the TCL1 mouse model which focus on the role of CD74, CD44 and 
CXCR2 in CLL development and nurse-like cell function.  
 
5.2 MIF inhibits apoptosis in vivo and in vitro 
The increased presence of CD68+ macrophages in normal and leukemic organs 
suggests that the surrounding B cells may receive enhanced pro-survival signals in vivo. 
Although CLL is characterized by a defect in the apoptotic machinery of the cell (Kitada et 
al., 1998), the CLL cells are nevertheless still prone to apoptosis and require constant 
stimulation by pro-survival factors in order to overcome spontaneous apoptosis. A higher 
rate of apoptosis may therefore be due to less anti-apoptotic stimulation.  
Our in vivo-experiment reveals that the rate of spontaneous apoptosis is increased in MIF-
deficient mice. The ex vivo experiments with pre-leukemic and leukemic splenocytes were 
less clear which may be due to MIF present in the FCS of the media used. Nevertheless, 
the treatment of splenocytes with cytostatic drugs commonly used in the treatment of CLL 
showed that pre-leukemic splenocytes had a near significant trend to higher apoptosis in 
the absence of MIF.  
A higher threshold for apoptosis in MIF-expressing animals or cells might be the reason 
for the accelerated accumulation of the malignant clone, leading to increased tumor load 
and reduced overall survival. We currently do not have an explanation why leukemic MIF-
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deficient splenocytes were less responsive to DNA damage. Further experiments are 
required to clarify the role of MIF in apoptosis regulation of leukemic cells.  
Treatment of the splenocytes ex vivo with the p53-inhibitor PFT-α and the CDC25-
inhibitor NSC during DNA damage induction with cytostatic drugs did not show any 
differences in the pre-leukemic cells. In both groups, cells behaved the same as with the 
normal fludarabine-treatment. This indicates that the mechanism of the cells undergoing 
apoptosis is p53-independent and also independent of CDC25. CDC25 phosphatase 
regulates the checkpoints of the G1-S and the G2-M transition and is known to be 
upregulated in different aggressive tumors and tumors with poor prognosis (Kristjansdottir 
and Rudolph 2004). We have indications that genetic inactivation of p53 may occur in the 
leukemias since we found cases with strongly overexpressed p53, a typical feature of 
mutated p53 (de Vries et al., 2002). Nevertheless, formal proof by sequencing is still 
outstanding. Alternatively, functional inactivation of p53 may also occur via p53 inhibitory 
molecules such as MIF (Hudson et al., 1999; Fingerle-Rowson et al., 2003; Talos et al., 
2005). In this context, it is noteworthy, that p53 overexpression occurred more frequently 
in MIF-expressing than in MIF-deficient leukemias.  
Bortezomib, a well known proteasomal inhibitor was chosen to test whether apoptosis 
induction was dependent on the known ability of MIF to increase SCF-dependent 
ubiquitylation and proteasomal degradation. Like the cytostatic drugs, bortezomib also 
induces apoptosis in CLL cells in vitro (Liu et al., 2008), effectively killed the malignant 
splenocytes but failed to abolish the difference. Still the TCL1+/wt MIF-/- splenocytes show 
a significantly higher rate of apoptotic cells after 24 h in comparison to the  
TCL1+/wt MIF+/+ cells (p = 0.02). Thus, the use of pathway inhibitors did not help to get 
further insights into the mechanism of MIF action in apoptosis of CLL cells. It has been 
shown recently that activation of CD74 via MIF leads to NF-κB activation which may also 
affect the rate of apoptosis in response to DNA damage. Therefore, additional experiments 
looking at NF-κB pathway activation in CLL are required in order to find out whether MIF 
involves the NF-κB pathway in vivo.  
 
5.3 MIF and in vitro and in vivo proliferation  
Our study of MIF-dependent proliferation in CLL yielded a more complex picture of 
what might be going on in vivo. 
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We found no differences in the rate of BrdU incorporation in B cells of the pre-leukemic 
animals of the TCL1+/wt MIF+/+ and the TCL1+/wt MIF-/- group. In contrast, in leukemic 
animals splenocytes from the MIF knockout mice showed more BrdU incorporation than 
the wildtype cells. This contrast to the effects seen in the apoptosis assay, but MIF is also 
described to act as a growth promoting molecule (Mitchell et al., 2002; Calandra and 
Roger 2003; Morand 2005; Swant et al., 2005; Bernhagen et al., 2007). We cannot prove 
but we speculate that the leukemic cells of the MIF-/- animals have a combined defect in 
cell cycle regulation, with both an increased rate of proliferation and an increased rate of 
apoptosis at the same time. Such effects may occur in molecules which regulate the G2-M 
checkpoint. Indeed, MIF has been found recently to act as an important regulator of the 
G2-M checkpoint on a p53-deficient background (Nemajerova et al., 2007).  
 
5.4 Spectral karyotyping highlights the importance of trisomy 15 in 
TCL1-driven leukemogenesis 
Typically, a dysregulation of G2-M checkpoint function leads to an accumulation of 
genomic damage in the following generation of daughter cells, and we therefore tested by 
SKY analysis whether the TCL1+/wt MIF-/- mice had accumulated more severe 
chromosomal aberrations. However, our set of SKY analyses in TCL1+/wt MIF-/- and 
TCL1+/wt MIF+/+ spleens could not prove this hypothesis, yet, but this may require a larger 
number of analyses. 
Nevertheless, in TCL1+/+ leukemic mice we found an almost 100 % incidence of  
trisomy +15, whereas all other genomic aberrations were less frequent. This suggests that 
trisomy +15 may be an important secondary genetic event leading to CLL development. 
The trisomy +15 aberration is described for many different mouse models, e.g. a model for 
Down’s syndrome (Morice et al., 2008) and also in the pEµ-B29-TCL1 mouse model, 
where TCL1 is overexpressed in T and B cells (Shen et al., 2006). In both cases, this 
trisomy goes ahead with overexpression of c-myc.  
It is known that the protooncogene c-Myc is located on murine chromosome +15 (Bain et 
al., 1997; Linardopoulos et al., 2000; Marinkovic et al., 2004). C-myc plays a pivotal role 
in the regulation of proliferation, differentiation and apoptosis (Askew et al., 1991; Shi et 
al., 1992; Evan and Littlewood 1993; Hoffman and Liebermann 1998). Alterations of  
c-myc on the protein-level are associated with many hematological malignancies, e.g. 
Burkitt’s lymphoma, T-ALL (T-cell acute lymphoblastic leukemia) or multiple myeloma 
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(Boxer and Dang 2001). Overexpression of c-myc is known to lead to progression in the 
G1-S phase of the cell cycle (Perez-Roger et al., 1999). In our mice, however, we do not 
observe a significant upregulation of c-myc in leukemic spleens. Currently, experiments 
are ongoing which measure c-myc gene expression in TCL1-induced leukemias of MIF 
wildtype and knockout mice.  
 
5.5 Outlook 
The role of MIF in the pathogenesis of murine CLL is partly explained by the results 
of this work. MIF acts as a tumor promoter and it recruits macrophages as potential nurse-
like cells to the infiltrate which in turn protect CLL cells from looming apoptosis. Our 
work also depicts downstream effects of MIF such as its contribution to apoptosis 
resistance, proliferation and clonal cytogenetic evolution of the leukemia. Our results bring 
also the tumor suppressor p53, the protooncogene c-myc as well as the surface receptors 
CD74, CD44 and CXCR2 into the larger picture of this mouse model. 
A lot more, but fascinating questions have been raised by this work. We will continue on 
this avenue primarily focussing on the role of MIF for nurse cell function in CLL. In 
addition, we are running experiments which aim at elucidating the contribution of CD74, 
CD44 and CXCR2 to the development of murine CLL.  
Our hope is that this work will provide a novel detail to the widening picture of how CLL 
develops and evolves in humans. With MIF being an extracellular molecule, we believe 
that targeting MIF in humans may be technically possible and scientifically reasonable for 
the treatment of human CLL.  
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6 Material 
6.1 Instruments 
Automatic pipettes Gilson, Middleton, WI, USA 
Balance Ohaus, Pine Brook, NJ, USA 
Cell counting chambers Neubauer, Germany 
Cell freezing containers Nalgene, Neerijse, Belgium 
Centrifuge (benchtop and 4°C) Eppendorf, Hamburg, Germany 
Centrifuge (cell culture) Eppendorf, Hamburg, Germany 
Electrophoresis system DNA BioRad, Hercules, CA, USA 
Electrophoresis system Protein Invitrogen, Karlsruhe, Germany 
Elisa-Reader µQant, BioTek, Bad Friedrichshall, Germany 
Film-developer AGFA, Cologne, Germany 
Films Amersham Bioscience, Buckinghamshire, UK 
Flow Cytometers  
   FACS Calibur BD Biosciences, Heidelberg, Germany 
   FACS Canto BD Biosciences, Heidelberg, Germany 
Fridge and Freezer  
   4°C & -20°C AEG, Stockholm, Sweden 
   -80°C Sanyo, Wood Dale, IL, USA 
Heater/ Magnetic Shaker Heidolph, Schwabach, Germany 
Incubator (mammalian cell culture) Labotect, Göttingen, Germany 
Laminar flow hood Heraeus, Hanau, Germany 
Microscope Axiophot,Zeiss, Göttingen, Germany 
 
Leica DM4000B, Leica Camera AG, Solms, 
Germany 
N2-storage tank Thermo Scientific, Dubuque, IA, USA 
PCR machine (Mastercycler gradient EP S) Eppendorf, Hamburg, Germany 
pH-Meter Mettler-Toledo, Schwerzenbach, Germany 
Shaker Heidolph, Schwabach, Germany 
Spectrophotometer BioRad, Hercules, CA, USA 
Thermomixer Eppendorf, Hamburg, Germany 
Vortex VWR, Darmstadt, Germany 
Waterbath Medingen, Freital, Germany 
X-ray film Exposure cassette AGFA, Cologne, Germany 
 
6.2 Materials 
Gel blotting paper Schleicher & Schuell, Dassel, Germany 
Hyperfilm ECL Amersham Biosciences, Buckinghampshire, UK 
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Parafilm American National Can, IL, USA 
Photometer cuvettes Sarstedt, Numbrecht, Germany 
Tissue culture material  
     Cell strainer BD Biosciences, Heidelberg, Germany 
     Cryotube vials Nunc, Roskilde, Denmark 
     Cell sracper TPP, Trasadingen, Switzerland 
     Flasks BD Biosciences, Heidelberg, Germany 
     Pipette tips, tubes, dishes  Sarstedt, Numbrecht, Germany 
 
6.3 Chemicals and Reagents 
2-Mercaptoethanol Sigma, Steinheim, Germany 
5’-Bromo-desoxy-uracil (BrdU) Sigma, Steinheim, Germany 
Acetic Acid Carl Roth GmbH & Co, Karlsruhe, Germany 
Acrylamid 30% Carl Roth GmbH & Co, Karlsruhe, Germany 
Agarose Biozym, Hess. Oldendorf, Germany 
Ammonium peroxdisulfate (APS) Carl Roth GmbH & Co, Karlsruhe, Germany 
Bromphenol blue Carl Roth GmbH & Co, Karlsruhe, Germany 
Bovine Serum albumin Applichem, Darmstadt, Germany 
Calcium chloride Merck, Darmstadt, Germany 
DMEM Gibco/Invitrogen, Karlsruhe, Germany 
DMSO Sigma, Steinheim, Germany 
ECL Amersham Biosciences, Buckinghampshire, UK 
Ethanol Carl Roth GmbH & Co, Karlsruhe, Germany 
Ethidiumbromide Carl Roth GmbH & Co, Karlsruhe, Germany 
Ethylendiamine tretra acetic acid (EDTA) Carl Roth GmbH & Co, Karlsruhe, Germany 
Fetal Calf Serum (FCS) Gibco/Invitrogen, Karlsruhe, Germany 
Glycerol Carl Roth GmbH & Co, Karlsruhe, Germany 
Glycine Carl Roth GmbH & Co, Karlsruhe, Germany 
Hepes Carl Roth GmbH & Co, Karlsruhe, Germany 
Hydrochloric acid Carl Roth GmbH & Co, Karlsruhe, Germany 
Isopropanol Carl Roth GmbH & Co, Karlsruhe, Germany 
Magnesium chloride Carl Roth GmbH & Co, Karlsruhe, Germany 
Methanol Carl Roth GmbH & Co, Karlsruhe, Germany 
Molecular weight marker MBI-Fermentas, St. Leon-Rot, Germany 
MTT Sigma, Deisenhofen, Germany 
Non fat dry milk powder Carl Roth GmbH & Co, Karlsruhe, Germany 
Nonidet P-40 (NP-40) Sigma, Deisenhofen, Germany 
Paraformaldehyde Sigma, Deisenhofen, Germany 
PBS Gibco/Invitrogen, Karlsruhe, Germany 
PCR Primers Metabion, Martinsried, Germany 
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Penicillin/Streptomycin Gibco/Invitrogen, Karlsruhe, Germany 
Ponceau S Carl Roth GmbH & Co, Karlsruhe, Germany 
Potassium Chloride Merck, Darmstadt, Germany 
Prestained protein marker MBI-Fermentas, St. Leon-Rot, Germany 
RPMI Gibco/Invitrogen, Karlsruhe, Germany 
Sodium chloride Carl Roth GmbH & Co, Karlsruhe, Germany 
Sodium dodecylsulfate (SDS) Serva Electrophoresis GmhH, Heidelberg, 
Germany 
Sodium pyruvate Gibco/Invitrogen, Karlsruhe, Germany 
TEMED Carl Roth GmbH & Co, Karlsruhe, Germany 
Tris –(hydroxymethyl)-aminomethane Carl Roth GmbH & Co, Karlsruhe, Germany 
Triton X-100 Sigma, Deisenhofen, Germany 
Trypan Blue Gibco/Invitrogen, Karlsruhe, Germany 
Trypsin/EDTA Gibco/Invitrogen, Karlsruhe, Germany 
 
6.4 Antibodies 
6.4.1 Antibodies for Western Blotting 
Antibody specificity Species Supplier 
Akt Rabbit polyclonal CellSignaling Technology, MA, USA 
ATM Mouse monoclonal Novus Biologicals, Littleton, CO, 
USA 
Bcl-2 Mouse monoclonal Santa Cruz Biotechnology, CA, USA 
c-myc Rabbit polyclonal Santa Cruz Biotechnoloy, CA, USA 
ERK1/2 (p44/42) Rabbit polyclonal CellSignaling Technology, MA, USA 
GAPDH Rabbit polyclonal Santa Cruz Biotechnoloy, CA, USA 
MDM2 Mouse monoclonal Santa Cruz Biotechnoloy, CA, USA 
MIF Rabbit polyclonal Invitrogen, Karlsruhe, Germany 
p19ARF Rabbit polyclonal Novus Biologicals, Littleton, CO, 
USA 
p53 Rabbit polyclonal VisionBiosystems Novocastra, 
Newcastle, UK 
Phospho-Akt Rabbit monoclonal CellSignaling Technology, MA, USA 
Phospho-ERK1/2 
(Phospho-p44/42) 
Rabbit monoclonal CellSignaling Technology, MA, USA 
β-actin Mouse monoclonal Sigma, Deisenhofen, Germany 
β-tubulin Rabbit polyclonal Santa Cruz Biotechnoloy, CA, USA 
TCL1 Mouse monoclonal Provided by Dr. M. Herling 
   
Secondary Antibodies   
Anti-mouse-IgG HRP-conjugated, goat Dako Cytomation, Glostrup, Denmark 
Anti-rabbit-IgG HRP-conjugated, swine Dako Cytomation, Glostrup, Denmark 
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Anti-mouse- IgG Biotinylated Dako Cytomation, Glostrup, Denmark 
Anti-rabbit-IgG Biotinylated Dako Cytomation, Glostrup, Denmark 
Anti-rat- IgG Biotinylated Dako Cytomation, Glostrup, Denmark 
6.4.2 Antibodies for FACS-Analysis 
Directly Labeled Antibodies  
CD19 APC-Cy7-conjugated BD Pharmingen, Heidelberg, Germany 
CD21/CD35 PE BD Pharmingen, Heidelberg, Germany 
CD23 PE-conjugated BD Pharmingen, Heidelberg, Germany 
CD25 APC BD Pharmingen, Heidelberg, Germany 
CD3 PE-Cy7-conjugated BD Pharmingen, Heidelberg, Germany 
CD4 PE-conjugated BD Pharmingen, Heidelberg, Germany 
CD44 PE-conjugated BD Pharmingen, Heidelberg, Germany 
CD45R/B220 APC-conjugated BD Pharmingen, Heidelberg, Germany 
CD45R/B220 PerCP-conjugated BD Pharmingen, Heidelberg, Germany 
CD5 PerCP-conjugated BD Pharmingen, Heidelberg, Germany 
CD74 FITC-conjugated BD Pharmingen, Heidelberg, Germany 
CD8a FITC BD Pharmingen, Heidelberg, Germany 
CD93 (AA4.1) FITC-conjugated BD Pharmingen, Heidelberg, Germany 
CXCR2 PE-conjugated BD Pharmingen, Heidelberg, Germany 
IgD PE-conjugated BD Pharmingen, Heidelberg, Germany 
IgM FITC-conjugated BD Pharmingen, Heidelberg, Germany 
IgM APC-conjugated BD Pharmingen, Heidelberg, Germany 
Isotype control Rat IgG2b FITC-conjugated BD Pharmingen, Heidelberg, Germany 
Isotype control Rat IgG2b PE-conjugated BD Pharmingen, Heidelberg, Germany 
 
6.4.3 Antibodies for Immunohistochemistry 
CD3 Rabbit  Thermo Fisher Scientific GmbH, Schwerte, Germany 
CD5 Rabbit Thermo Fisher Scientific GmbH, Schwerte, Germany 
CD20 Mouse Thermo Fisher Scientific GmbH, Schwerte, Germany 
CD68 Mouse Thermo Fisher Scientific GmbH, Schwerte, Germany 
CD79a Rabbit Thermo Fisher Scientific GmbH, Schwerte, Germany 
p53 Rabbit Thermo Fisher Scientific GmbH, Schwerte, Germany 
 
6.5 Mouse strains 
MIF-/- mouse Homozygous knockout of the MIF gene (Fingerle-Rowson et al., 2003) 
MIF+/+ mouse Wildtype control   C57Bl/6, Charles River 
TCL1+/+ mouse Transgenic overexpression of TCL1 (Bichi et al., 2002) 
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6.6 Primers for Genotyping 
MIF-A1 5’ – AGG TTA GTC ACT CTA CTG GCC – 3’ 
MIF-B1 5’ – TCT CAC TGT TCT GGT GTG AGG – 3’ 
MIF-C1 5’ – GGC TCC TGG TCT CAG TCA GG – 3’ 
TCL1-reverse 5’ – CAT CTG GCA GCA GCT CGA – 3’ 
TCL1-universal 5’ – GCC GAG TGC CCG ACA CTC – 3’ 
 
6.7 Special Reagents and Kits 
Reagents/Kits Supplier 
Annexin V-PE Apoptosis 
detection kit 
BD Bioscience, Heidelberg, Germany 
BrdU Flow kit BD Bioscience, Heidelberg, Germany 
ClickIt EdU detection kit Invitrogen, Karlsruhe, Germany 
ECL Detection Reagents Amersham Bioscience, Buckinghamshire, UK 
Mouse on Mouse Kit Thermo Fisher Scientific GmbH, Schwerte, Germany 
Protease Inhibitor Cocktail Roche, Mannheim, Germany 
DeadEnd Fluorimetric TUNEL 
assay 
Promega, Mannheim, Germany 
NE-PER Nuclear and Cytoplasmic 
Extraction Reagents 
Pierce Biotechnology, Rockford, IL, USA 
NSC-663284 Tocris Bioscience, Ellisville, MO, USA 
PFT-α Sigma, Deisenhofen, Germany 
 
6.8 Abbreviations 
A Adenine 
C Cytosine 
G Guanine 
T Thymine 
APS Ammoniumpersulfate 
BPB Bromphenol blue 
BrdU 5’-Bromo-desoxy-uracil 
CD Cluster of Differntiation 
CDK Cyclin dependent Kinase 
CDKI Cyclin dependent Kinase inhibitor 
CLL Chronic lymphocytic Leukemia 
DDT D-Dopachrome Tautomerase 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethylsulphoxide 
DNA Desoxyribonucleic acid 
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EDTA Ethylene diamine tetraacetic acid 
ERK Extracellular signal-regulated kinase 
FCS fetal calf serum 
Ig Immunoglobulin gene 
Jab1 c-Jun-activating binding protein-1 
LPS Lipopolysaccharid 
MAPK Mitogen activated protein kinase 
MEF murine embryonal fibroblast 
MIF macrophage migration inhibitory factor 
MIF-/- MIF-knockout mouse 
MIF+/+ MIF-wildtype mouse 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NF-κB Nuclear factor kappa B 
NSC-663284 6-Chloro-7-[[2-(4-morpholinyl)ethyl]amino]-5,8-quinolin edione 
PBMC peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PFT-α 2-(2-Imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolylethanone 
hydrobromide 
PI Propidium iodide 
PI3K Phosphoinositide 3-kinase 
PKB Protein kinase B 
RPMI Roswell Park Memorial Institute Medium 
SDS Sodiumdodecylsulfate 
SDS-PAGE SDS-Polyacrylamide gelelectrophoresis 
TBS Tris buffered saline 
TCL1 T-cell leukemia 1 
TCL1+/+ T-cell leukemia 1 transgenic mouse, homozygous 
TCL1+/wt T-cell leukemia 1 transgenic mouse, heterozygous 
TCR T-cell receptor 
Tris tris-(hydroxymethyl)-aminomethane 
ZAP-70 zeta-chain associated protein-70 
 
6.9 Software 
BD FACS DIVA 
BD Cellquest Pro  
Endnote 
KC4  
Microsoft Office 
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Statistica 
SPSS 
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7 Methods 
7.1 Breeding 
Breeding of MIF -/- animals to TCL1+/+ transgenic mice was done in the animal 
facility of surgery which is run by the Clinic I of Internal Medicine at the University 
Hospital of Cologne.  
The two strains were bred with each other to obtain TCL1+/wt MIF-/- and TCL1+/wt MIF+/+ 
animals. As the TCL1+/+ mouse was bred on a B6C3H background and the MIF-/- mouse 
was developed on a C57Bl/6 background, the breeding strategy resulted in a mixed 
genetic background. 
The animals were kept at a controlled atmosphere. Semi-annual health checks showed 
that the mice were virus-free and only carried Helicobacter species as well as Pasteurella 
pneumonia without clinical signs of disease. The animals were allowed to feed and drink 
ad libitum and were held on a special breeding diet. They were kept in type II cages at 
groups of four to five mice.  
Breeding was done on a one to one basis and pups were weaned after 21 days.  
 
7.2 Genotyping 
Genotyping of the animals is necessary to determine the correct experimental animals 
from the controls and is done by polymerase-chain reaction (PCR). At the time of 
weaning, a piece of the tail is cut; DNA is prepared and the region of interest amplified by 
PCR with gene-specific primers. 
 
7.2.1 DNA-Preparation 
DNA from mouse tails was prepared: A piece of tail is put into a tube and lysed over 
night in 500 µl of lysis buffer plus 10 µl of Proteinase K (1 mg/ml) in a thermomixer at 
56 °C and 700 rpm.  
The next morning the digested tail is centrifuged at 13000 rpm for 10 minutes. The 
supernatant is put into a new cup with 500 µl of isopropanol, mixed and again centrifuged 
for 10 min at 13000 rpm. Discard supernatant and wash pellet twice with 200 µl of 70 % 
ethanol. Discard ethanol and dry pellet for 30 minutes at room temperature. When the 
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pellet is dry (no more smell of ethanol) it was resuspended pellet in 100 µl of TE-buffer. 
Leave the DNA at 4 °C over night to dissolve. 
DNA lysis buffer:  100 mM Tris, pH 8.5 
    5 mM EDTA 
    0.2 % SDS 
    200 mM NaCl 
    ad 1 l ddH20 
 
1 x TE-buffer:   50 mM Tris 
    150 mM NaCl 
    adjust to pH 7.5 
    ad 1 l ddH20 
 
7.2.2 Polymerase-Chain-Reaction (PCR) 
Amplification of DNA fragments is done by polymerase-chain-reaction (PCR). A 
piece of DNA is amplified with specific primers binding to the gene of interest. The 
amplification is done with a Taq (named after the thermophilic bacterium Thermus 
aquaticus) -polymerase by in vitro enzymatic replication. The generated DNA is itself 
used as a template again, so the chain reaction amplifies the DNA exponentially.  
Set up the genotyping-PCR by pipetting the mastermix (23 µl per reaction) plus 1 µl of 
each primer and 1 µl of DNA into a 0.5 ml eppendorf cup. Add 0.4 µl of Taq-polymerase 
to the reaction and start the program on Eppendorf mastercycler S gradient. 
Mastermix:   100 µl 10 x Taq-buffer 
   66 µl MgCl2 (equates to 1.5mM) 
   100 µl dNTP’s (10 mM each) 
    734 µl ddH20 
 
TCL1-PCR:  Initiation  94 °C 2 min 
  Denaturation  94 °C  1 min 
  Annealing  62 °C  45 sec 
  Elongation  72 °C  2 min  35 cycles (step 2, 3 and 4) 
  Final elongation 72 °C  5 min 
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MIF-PCR:  Initiation  94 °C  2 min 
  Denaturation  94 °C  1 min 
  Annealing  62 °C  45 sec 
  Elongation  72 °C  45 sec  35 cycles (step 2, 3 and 4) 
  Final elongation 72 °C  10 min 
 
7.2.3 Agarose Gel Electrophoresis 
PCR products as well as restriction enzyme digests were analysed by agarose gel 
electrophoresis to verify the size of the fragments or products. 
Therefore 1 x TAE buffer was boiled with the desired amount of agarose, mixed with the 
intercalating substance ethidium bromide (0.25 µg/ml) and poured into the gel chamber. 
The comb was directly inserted and taken out when solidification occurred before the 
chamber was put into the electrophoresis chamber containing 1 x TAE. For large 
fragments 0.8 % agarose, for smaller ones 2 % was used. 300 to 500 ng of restriction 
digested DNA or 10 µl of PCR products were mixed with loading dye filled up with H20 
to a final volume of 20 µl and loaded onto the gel. Depending on size of the gel, between 
80 and 140 V and 200 mA was chosen for electrophoresis. 
50x TAE-buffer:  dissolve 242 g of Tris in 500 ml of ddH20 
   50 mM Na2EDTA 
   57.1 ml glacial acetic acid 
   ad 1 l ddH20 
 
7.3 Blood-Analysis 
7.3.1 Bloodsampling 
For the analysis of leukemia, blood of the experimental mice is taken every three 
months from the tail vein. Mice are warmed up under red-light to improve blood flow. A 
little cut at the end of the tail is done by a scalpel and the blood is collected in a tube 
containing 10 µl of 0.5 M EDTA, to prevent the blood from clotting. 100 µl of blood is 
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taken from each mouse which is then further checked for leukemia in the blood counts 
and by FACS for the percentage of malignant cells.  
 
7.3.2 Differential Blood Count 
To determine the complete blood count, blood is diluted 1:10 with CellPack (BD 
Biosciences) and measured on a Sysmex XE-2100. Characteristics of the cells are 
measured by lasers (flow cytometry) where the blood is separated by a semiconductor 
into a number of channels. The XE-2100 has got five different channels, differentiating 
the white blood count, the differential leukocyte count as well as reticulocyte count and 
fluorescence platelet count. 
 
7.3.3 Flow Cytometry 
Fluorescence activated cell sorting (FACS) provides a method to study cells based 
upon the specific light scattering and fluorescent characteristics of each cell. Expression 
of proteins either surface proteins or intra-cellular proteins can be detected by staining the 
cells with fluorescently-labelled antibodies, whereas cells expressing endogenous 
fluorescent proteins can be detected directly.  
To determine the grade of leukemia, blood of the mice is labelled with the surface 
receptor antibodies IgM and CD5. 30 µl of blood was pipetted into a Facs tube and 
incubated with 1 µl of anti-IgM and 1 µl of anti-CD5 antibody at room temperature in the 
dark. After 20 min, 2 ml of 1x ACK buffer was added to the cells and incubated on ice for 
exactly 4 min. Cells were then spun down at 1200 rpm for 5 min followed by a washing 
step with 3 ml of PBS. Cells are pelleted again and resuspended in 150 µl of PBS for 
FACS analysis on the FACS Canto. 
10x ACK buffer:  82.9 g ammonium chloride 
   10 g potassium bicarbonate 
   0.37 g EDTA 
   ad 1 l ddH2O 
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7.4 Extraction of organs 
Organs from the animals were taken out for further examination. If an animal dies or 
is euthaniesed because of severe disease, organs like spleen, bone marrow, liver and 
lymph nodes were taken out and fixed in a 4 % formalin solution and stored in the dark 
for maximum two weeks. After fixation, the organs where processed in the Thermo 
Fisher Scientific and embedded into paraffin. Before fixation, parts of the spleen were 
prepared for further ex vivo analysis by FACS, for detection of the malignant clone or 
apoptosis and proliferation. 
 
7.5 Eukaryotic cell culture 
7.5.1 Culture conditions 
All cell lines and primary cells were cultured at 37 °C, a relative humidity of 90 % 
and 5 % CO2. DMEM cell culture media was supplemented with 10 % (v/v) FCS, 1 % 
Na-pyruvate and 1 % Penicillin / Streptomycin. RPMI cell culture medium is 
supplemented with 10 % (v/v) FCS, 1 % Hepes-buffer and 1 % Penicillin / Streptomycin.  
 
7.5.2 Trypsinization 
To detach adherent cells from culture dishes, media was taken off and cells were 
washed with PBS to remove rests of medium. Cells were then incubated in a small 
volume of trypsin / EDTA in the incubator until detachment is visible. The reaction was 
stopped by adding the same volume of media containing 10 % FCS.  
 
7.5.3 Counting 
After trypsinization, cells were diluted with trypan blue. Trypan blue is a vital stain 
which selectively stains dead cells blue. 10 µl of dilution were transferred into a 
“Neubauer” chamber. Four squares were counted and an average was calculated. The 
number of cells (n) in one square equals n x 104 per ml divided through dilution factor of 
trypan blue. 
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7.5.4 Freezing and thawing of Cells 
Cells were grown to confluence, trypsinized and pelleted at 1200 g for 5 min. They 
were then resuspended in freezing medium containing 80 % FCS and 10 % DMSO. 
Aliquots were pipetted into cryotubes and frozen at –80 °C in freezing containers. For 
long term storage the cryotubes were transferred into the liquid nitrogen tank after one to 
two days. 
For thawing the cells, frozen vials were taken out of the liquid nitrogen tank, carefully 
thawed at 37 °C in the water bath and immediately transferred into a 15 ml tube 
containing 5 ml of prewarmed culture medium. Pelleting the cells by centrifugation at 
1200 g for 5 min removes the toxic DMSO. After resuspension of the cells in fresh 
culture medium the cells were plated into a 10 cm plate.  
 
7.5.5 Primary splenocytes 
Primary splenocytes of TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- were prepared for 
apoptosis, proliferation tests and chromosomal preparations. The animal was killed by 
cervical dislocation and the abdominal cavity was opened. First the overall appearance of 
the animals’ organs is checked to see whether there are any abnormalities. Then the 
spleen is taken out by opening the peritoneum getting it with two tweezers. The organ is 
then put into a cell strainer (BD, 100 µm diameter) in a 50 ml falcon and a single cell 
suspension is done by grinding the spleen through the mesh with a syringe. Rinse the 
mesh with 5 - 10 ml of RPMI media (depending on the size of the spleen) and spin down 
the cells. Lyse red blood cells with 1x ACK buffer for 5 min on ice, spin again and wash 
cells with 5ml of PBS. Count cells and plate the appropriate number of cells into well-
plates for the required experiments. 
 
7.6 Protein biochemistry 
7.6.1 Preparation of cell lysates 
To detect the expression pattern of different proteins, they have to be separated on a 
gel.  
A cell pellet of 1 x 107 cells is washed twice in PBS and then lysed in 100 µl of Joe’s 
lysis buffer, sonicated with an ultrasound-sonicator for 20 seconds. The lysed proteins 
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were spun down in a cooling centrifuge at 400x G for 30 minutes. After centrifugation the 
clear lysate is transferred into a new tube and then the protein content is determined. 
Joe’s Lysis buffer:  25 mM Hepes, pH 7.7 
   400 mM NaCl 
   1.5 mM MgCl2 
   2 mM EDTA 
   0.5 % Triton X-100 
   ad 1 l ddH20 
 
7.6.2 Quantification of Proteins 
The protein concentration is determined by a Bradford assay, preparing a standard 
curve with BSA. Standard proteins and cell lysates are mixed with Roti-Nanoquant 
(Roth), which was diluted 1:5 in ddH2O. 
For the assay, 2 µl of protein lysate was mixed with 1000 µl of Roti-Nanoquant. To 
prepare protein standards for calibration of the reader, 2, 4, 6, 8 and 10 µg of bovine 
serum albumin from a 1 mg/ml stock was diluted in Roti-Nanoquant. 200 µl of this 
dilution was pipetted into a 96-well plate, also the dilution of the protein samples. The 
determination of the protein concentration was measured at wavelengths of 450 nm and 
590 nm as a reference, using a spectrophotometer. A standard curve of absorbance minus 
micrograms protein was plotted (OD590/OD450) and the protein concentration of each 
sample was determined by the linear regression.  
 
7.6.3 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
In SDS-polyacrylamide gel electrophoresis (SDS-PAGE), proteins are separated on 
the basis of their molecular weight.  
Two sequential gels were casted, the top gel, so called stacking gel is slightly acidic (pH 
6.8) and has a low polyacrylamide concentration, where the proteins are poorly separated 
but form thin and sharply defined bands. The lower gel, the separating or resolving gel, is 
more basic (pH 8.8) and has a higher polyacrylamide content, which allows the proteins 
to be separated according to their molecular sizes, where smaller proteins travel faster 
than the larger proteins. Sodium-dodecyl-sulfate (SDS), an anionic detergent, denatures 
the protein and imparts a negative charge, while β-mercaptoethanol, a hybrid of ethylene 
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glycol breaks disulfide bonds in the proteins. In an electric field, the negatively charged 
proteins are attracted towards the anode and they are resolved solely on the basis of their 
sizes by the pores of the polyacrylamide gel.  
Electrophoresis was carried out using a vertical apparatus Mini Protean II (BioRad, 
Munich, Germany). Protein samples for electrophoresis are prepared by adding 4x sample 
buffer and boiling the mixture at 95 °C for 5 min. Equal amounts of protein samples and 
the molecular weight marker were loaded in the slots of the stacking gel. Gels were run at 
100 V, until the blue running front has travelled to the bottom of the separating gel.  
 
Solutions for casting SDS-Polyacrylamide gels: 
Solutions Stacking gel             Resolving gel 
  10 % 15 % 
ddH20 2.5 ml 2.075 ml 2.075 ml 
1.5 M Tris (pH 6.8) 1.25 ml                ------ 
1.5 M Tris (pH 8.8)      ---- 0.825 ml 2.075 ml 
30 % Acrylamide 1.25 ml 0.33 ml 2.075 ml 
10 % SDS 50 µl 33 µl 33 µl 
10 % APS 13.3 µl 17 µl 33 µl 
TEMED 6 µl 3.3 µl 33 µl 
 
Electophoresis buffer  192 mM Glycin 
    25 mM Tris 
    0.1 % SDS (v/v) 
 
4x sample buffer  50 ml 1 M Tris pH 6.8 
    30 ml ddH20 
    20 ml Glycerol 
    4 g SDS 
    200 mg Bromphenolblue 
   before use add 200 µl of β-mercaptoethanol to 4.8 ml of stock 
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7.6.4 Protein Transfer 
For the detection of the protein of interest, the resolved protein bands on the gel are 
transferred on to blotting membranes by the process referred to as blotting. The blotting 
process was achieved by using Trans-blot cell wet transfer apparatus.  
Proteins were transferred onto nitrocellulose membranes. Membranes, filter paper and 
fibre pads were all pre-soaked in the transfer buffer. 
The following is the order of assembly of the module (sandwich-blotting chamber): 
   Anode (white) 
   Fibre pad 
   Filter paper 
   Membrane 
   Gel 
   Filter paper 
   Fibre pad 
   Cathode (black) 
Care should be taken to remove all the air bubbles in the assembly. The transfer was 
carried out at 100 V for 60 min.  
Transfer Buffer:   250 mM Tris 
    200 mM Glycine 
    20 % Methanol 
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7.6.5 Immunoblotting and Development 
Immunoblotting involves the detection of specific proteins on membranes using 
antibodies. The membranes are first blocked with blocking reagent (5 % non fat dry milk 
in PBS or 5 % BSA in TBS-T) to prevent non-specific binding of antibodies. Then, 
primary antibodies that recognize specific proteins are allowed to bind to their targets. 
Respective primary antibodies are diluted in the blocking reagent and incubate the 
membrane over night at 4 °C on a shaker. After three washing steps, 10 min each with 1x 
PBS or TBS-T to remove non-specific binding and excess antibody, secondary antibodies 
labelled with horseradish peroxidase (HRP), that recognize the primary antibodies are 
applied to the membrane. The secondary antibody is also diluted in the blocking reagent 
and incubated with the membrane for 60 min at room temperature. Thereafter the 
membrane is washed again three times with 1x PBS or TBS-T for 10 min before detection 
of the protein by chemoluminescent visualization using the enhanced chemoluminescent 
(ECL) detection system. For the detection 1 ml of freshly prepared ECL working solution 
is prepared by mixing Solution A and B in a ratio of 1:1 (v/v). The mixture is 
immediately spread on the membrane and incubated for 1 min. Excess solution is drained 
off and the membrane was exposed to Hyperfilm in the dark for the appropriate time and 
developed in an X-ray film processor.  
 
10x PBS buffer:  80 g NaCl 
    2 g KCl 
    26.8 g Na2HPO4-7H2O 
    2.4 g KH2PO4 
    ad 1 l ddH20, adjust pH to 7.4 
 
TBS buffer:    10 mM Tris-HCl, pH 8.0 
    150 mM NaCL 
TBS-T buffer:  1 % (v/v) Tween-20 in TBS buffer 
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7.7 Quantification of Apoptosis 
7.7.1 Annexin V and 7-AAD staining 
The phospholipid phosphatidylserine (PS) is translocated from the inner cytosolic 
leaflet of the plasma membrane bilayer to the outer cell surface, indicating the early 
events of the apoptosis machinery. Annexin V is a 35 kDa phospholipid-binding protein 
with high affinity for PS. PS inversion is also a phenomenon occurring during necrosis, 
so in order to differentiate apoptosis and necrosis, Annexin V staining is accompanied 
with a vital dye, 7-amino-actinimysin D (7-AAD), which stains the nucleic acid only 
when the membrane integrity is lost.  
Splenocytes from TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice were isolated from the 
spleen as described in chapter 7.5.5. After preparation and cell count, 1 x 105 cells were 
plated into a 96-well plate in a volume of 100 µl. To induce apoptosis, cells were either 
treated with cytostatic drugs or left untreated until a total volume of 200 µl was reached. 
Treated and untreated cells are incubated for 8 and 24 hours in an incubator at 37 °C and 
5 % CO2. After the incubation times, cells were pipetted into Facs tubes and washed once 
with 3ml of PBS and centrifuged at 1200 rpm for 5 min. After this step, cells were 
resuspended in 100 µl of Annexin binding buffer containing 1 µl of Annexin V and 1 µl 
of 7-AAD. The samples were then incubated at room temperature in the dark. After 20 
min, the samples are analysed using the FACS-Calibur cytometer. The percentages of 
treated Annexin V positive cells (% apoptotic) were compared to untreated cells.  
 
7.7.2 TUNEL assay 
For detection of apoptosis in vivo, paraffin embedded sections of spleen were stained 
for dT-mediated dUTP-biotin nick end labelling (TUNEL). TUNEL measures nuclear 
DNA fragmentation, an important biochemical hallmark of apoptosis, in cells.  
We used the Dead End Fluorimetric TUNEL System (Promega, Madison, WI, USA), 
which is a non-radioactive system, measuring apoptotic cells by catalytical incorporation 
of fluorescein-12-dUTP at the 3’-OH end of the DNA.  
Sections of the spleen were deparaffinised in xylene for 5min, followed by a washing step 
in 100 % ethanol for 5 min. After that, sections were rehydrated by a descending ethanol 
series (100 %, 95 %, 85 %, 70 %, 50 %) for 3 min each. Another washing step in 0.85 % 
NaCl follows, then a wash in PBS. Sections have to be fixed by an incubation step in a 4 
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% methanol-free formaldehyde solution for 15 min. The samples were washed again two 
times in PBS for 5 min each. The liquid has to be removed from the tissue and the slides 
have to be put on a flat surface for the incubation with 100 µl of a 20 µg/ml Proteinase K 
solution for 10 min. Tip off the Proteinase K and wash the samples twice in PBS for 5 
min, followed by another fixation step in 4 % methanol-free formaldehyde solution for 5 
min and another wash in PBS for 5 min.  
For a positive control, incubate one sample with DNase I to cause DNA fragmentation. 
Therefore 100 µl of DNase I buffer (40 mM Tris-HCl, pH 7.9, 10 mM NaCl, 6 mM 
MgCl2, 10 mM CaCl2) is added to the sample and incubated for 5 min followed by 
incubation with DNase I buffer containing 10 units/ml of DNase I for 10 min. Slides need 
to be washed extensively three to four times in ddH2O. Positive controls need to be 
processed in extra Coplin jars now, due to residual DNase I activie which my introduce 
background staining in experimental slides.  
Slides were then pre-incubated with 100 µl of Equlibration buffer (provided) for 5 – 10 
min. In the meantime, the reaction mix is prepared sufficient for all samples according to 
the following table: 
Buffer 
component 
Component 
volume per 
standard 50 µl 
reaction  
Number of 
reactions 
(experimental 
reactions + positive 
control)  Component volume 
 
Equlibration  
buffer 45 µl x ____ = ____µl 
 
Nucleotide mix 5 µl x ____ = ____µl 
 
rTdT Enzyme 1 µl x ____ = ____µl 
      
 
For the negative control, prepare a control incubation buffer without the enzyme. Most of 
the equilibration buffer hast to be removed from the slides, then the cells were incubated 
with 50 µl of prepared rTdT incubation buffer. To protect the samples from drying out, 
they need to be covered with plastic coverslips, also to ensure even distribution of the 
reagent. Put the samples in a humidified chamber covered with aluminium foil to protect 
the samples from light for 60 min at 37 °C. 
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After that time, the reaction was terminated by putting the slides in 2x SSC for 15 min at 
room temperature in the dark. Wash the samples three times in PBS for 5 min each to 
remove the unincorporated fluorescein-12-dUTP. Stain the sample in a freshly prepared 
propidium iodide (PI) solution (1 µg/ml PI in PBS) for 15 min in the dark to stain the 
nuclei. Wash the samples again twice in PBS and mount the slides with Mowiol using 
glass coverslips. 
The samples are then analysed under a confocal microscope (Olympus FluoView 1000). 
A confocal microscope uses point illumination and a pinhole in an optically conjugate 
plane in front of the detector to eliminate out-of-focus information. Only the light within 
the focal plane can be detected, so the image quality is much better than that of wide-field 
images. 
20x SSC:  87.7 g NaCl 
   44.1 g sodium citrate 
   adjust pH to 7.2, ad 500 ml ddH20 
 
7.8 Quantification of Proliferating Cells 
7.8.1 In vivo 
TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- mice are treated with 5-bromo-2-deoxyuridine 
(BrdU). BrdU is injected i.p. into the animals at a concentration of 50 µg/g of bodyweight 
over four days constantly. On the fifth day the animal is killed and spleen, blood, fluid of 
the peritoneal cavity and bone marrow are checked for the incorporation of BrdU.  
106 cells per 50 µl of staining buffer (PBS + 3 % FCS + 0.09 % sodium azide) are 
incubated with the cell surface markers CD5 and IgM for 15 min in the dark on ice. After 
the incubation time, cells are washed with 1 ml of staining buffer for 5 min at 300 x g, 
followed by a fixation and permeabilization step. The cell pellet is resuspended in 100 µl 
of BD Cytofix/Cytoperm buffer an incubated for 30 min on ice, followed by another 
washing step. Cells are then resuspended in 100 µl of the BD Cytoperm Plus buffer for 10 
min on ice, again followed by a wash and another re-fixation step in 100 µl BD 
Cytofix/Cytoperm buffer. After the incubation of 5 min at roomtemperature cells are 
washed and then resuspended in 100 µl of DNase (300 µg/ml) and incubated for 1 hour at 
37 °C to expose the incorporated BrdU. Resuspension of the cells in 50 µl of BD 
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wash/Perm buffer containing the fluorescent anti-BrdU antibody follows another washing 
step. Cells are now incubated for 20 min at room temperature in the dark, washed once 
more and then analysed on the FACS Canto.  
 
7.8.2 In vitro 
Splenocytes from mice of the genotype TCL1+/wt MIF+/+ and TCL1+/wt MIF-/- are 
taken and pulsed with 5-ethynyl-2´-deoxyuridine (EdU), an alternative for BrdU. EdU 
also incorporates into the DNA during DNA synthesis. 106 splenocytes are taken and 
incubated with 1 µg/ml of lipopolysaccharid (LPS) to stimulate DNA synthesis. After 24 
h cells are pulsed with 7.5 µg/ml EdU to analyse the incorporation after another 24 h 
respectively 48 h.  
Before analysis on the FACS Canto, cells need to be harvested, washed one with PBS + 1 
% BSA for 5 min at 500 x g. Cells are then resuspended in 100 µl of PBS + 1 % BSA and 
incubated with the cell surface antibodies CD5 and IgM for 15 min at room temperature. 
After another washing step cells are resuspended in 100 µl of Click-iT fixative and 
incubated for 15 min at room temperature protected from light. After another washing 
step cell are proceeded to cell permeabilization by washing with 3 ml of 1x saponin-based 
permeabilization buffer, followed by incubation with 500 µl of the Click-iT reaction 
cocktail for 30 min at room temperature. For one reaction the Click-iT reaction cocktail 
contains of: 
Reaction component  
1x Click-iT Reaction Buffer 487 µl 
CuSO4 10 µl 
Fluorescent dye azide 2.5 µl 
Reaction Buffer Additive 50µl 
Total volume 500 µl 
 
Cells are washed again with 3 ml of 1x saponin-based permeabilization reagent and then 
analysed on the FACS Canto.  
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7.9 Chromosomal preparation 
Primary splenocytes are isolated from the spleen, counted and then put into a 10 ml 
cellculture flask. 1 x 105 cells are plated in RPMI-medium supplemented with 10 % FCS, 
Hepes and sodium-pyruvate. Stimulation is done by treatment of the cells with LPS, 
ConcanavalinA and β-mercaptoethanol. Cells are stimulated for 48 hours, and then 
treated with Colcemid, a cell cycle-inhibitor. The cells are incubated for another 24 hours 
to arrest the cells in G1S-phase.  
For the preparation of metaphases, cells are collected and put into a 15 ml centrifugation 
tube and centrifuged for 10 min at 1500 rpm. Discard the supernatant and leave ~2 ml 
above the pellet and resuspend on a vortex. Fill tube up to 12 - 13 ml with prewarmed 
KCl, vortex and incubate at 37 °C for exact 20 min. Add freshly prepared fixative 
(methanol-acetic acid 3:1) under vortexing and centrifuge for 10 min at 1500 rpm. 
Disgard supernatant, leave again 2 ml above pellet, resuspend pellet and add freshly 
prepared fixative under vortex. Centriguge for 10 min at 1500 rpm and repeat this step 
three to four times. Place one drop of suspended pellet with a glass-pipette onto a pre-
cooled glass-slide and check chromosomes under a microscope. If there are too many 
cell-rests, wash cells again with fixative. Prepared chromosomes can be kept at -20 °C for 
up to two years.  
Preparation and analysis was done in cooperation with the group of Dr. Cornelia Rudolph 
from the Medizinische Hochschule Hannover.  
 
7.10 Immunohistochemistry 
Paraffin-embedded organs are cut on a microtome in the institute of pathology of the 
University Clinics Cologne. The sections have a diameter of 3 µm. 
For immunohistochemical staining, sections are labelled with the desired antibody. 
Before staining with the antibody, sections are deparaffinised in xylene for 20 min, then 
rehydrated in a descending ethanol series (three times 100 % EtOH, three times 70 % 
EtOH; 2 - 4 min each) and rinsed in deionised H2O. Depending on the antibody, the slides 
had to be pretreated with different buffers of different pH (see following table).  
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Antibody Pre-treatment Incubation -time and –
temperature 
CD3 Target Retrieval Solution pH 9 (Dako 
Cytomation #S2367) 
15 min, 95 °C 
CD5 Target Retrieval Solution pH 9 (Dako 
Cytomation #S2367) 
15 min, 95 °C 
CD20 Target Retrieval Solution pH 9 (Dako 
Cytomation #S1699) 
15 min, 95 °C 
CD68 Proteolytic Enzyme (Dako Cytomation 
#S3007) 
5 min, room temperature 
CD79a Target Retrieval Solution pH 9 (Dako 
Cytomation #S2367) 
15 min, 95 °C 
 
After pre-treatment, slides are washed in TBS-T for 5 min and then blocked with Thermo 
Ultra Block (# TA125UB) for 10 min and then incubated with the primary antibody for 
45 to 60 min, depending on the antibody. After another washing step with TBS-T, the 
slides are incubated with LAB Polyvalent Alk Phos Polymer (Thermo #TL-125-AL) for 
15 min and then developed with the UltraVision Detection System Liquid Fast Red 
Substrate System (Thermo #TA-060-AL).  
While development with FastRed the slides have to be watched under a microscope that 
there is no background stain. After the development slides are counterstained with a 
hemalaun solution for 1 min and embedded with AquaTex.  
To get an overview of the infiltration by lymphocytes in the organs, the slides are stained 
for Giemsa. Erythrocytes in the organs stain pink, platelets show a light pale pink, 
lymphocyte cytoplasm stains sky blue, monocyte cytoplasm stains pale blue, and 
leukocyte nuclear chromatin stains magenta. To stain the organs, slides need to be 
deparaffinised as aboveand then satined in Giemsa-buffer for 30 min. This stain is 
followed by a short dip in acetic acid to intensify the red, rinsed shortly with ddH2O and a 
dip into 96 % EtOH to remove the excess blue, three washes in 100 % EtOH and two dips 
into xylene. The slides need to be embedded fast, otherwise the staining will be lost.  
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